Antibodies directed to claudin 18.2, including bispecific formats thereof

Abstract

The disclosure is directed to an antibody specific for Claudin 18.2 and CD3. The present disclosure describes the isolation and characterization of antibodies, antibody fragments, and antibody variants specific for Claudin 18.2 and CD3.

Description

ANTIBODIES DIRECTED TO CLAUDIN 18.2, INCLUDING BISPECIFIC FORMATS THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The invention claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 606,967, filed December 6, 2023, the disclosure of which is hereby incorporated by reference in its entirety for all purposes.FIELD OF THE DISCLOSURE

[0002] The disclosure is directed to compositions that bind Claudin 18.2 and related methods.BACKGROUND

[0003] Cell adhesion proteins are critical for maintaining tissue integrity, as well as regulating diverse cellular events in a wide variety of physiological and pathological processes. Among cell adhesion proteins, some members of the claudin (CLDN) family are often aberrantly expressed in various cancers. Clinical application of CLDN therapeutics has been difficult because of lack of antibody specificity for particular CLDN proteins and widespread expression of closely related CLDN family members in normal cells. Thus, there remains a significant need for improved compositions and methods that can modulate the activity of CLDN family members to treat various cancers and diseases.SUMMARY

[0004] Accordingly, in various aspects, the present disclosure relates to a composition that specifically binds to Claudin 18.2 and CD3. The present disclosure describes the isolation and characterization of antibodies, antibody fragments, and antibody variants specific for Claudin 18.2 and CD3. In some embodiments, the antibody is a tandem single-chain variable fragment (scFv) specific for Claudin 18.2 and CD3 (FIG. 1A). In some embodiments, the antibody is a hetero VH IgG (FIG. 1B) specific for Claudin 18.2 and CD3. In some embodiments, the antibody is in the format of an scFv-Fab IgG antibody, which is illustrated as, for example, in FIG. 1C and is specific for Claudin 18.2 and CD3. In some embodiments, the antibody in the format of an IgG-scFv, which is illustrated as, for example, in FIG. 1D and is specific for Claudin 18.2 and CD3. In some embodiments, the antibody is in an IgG- (scFv)2format , which is illustrated, for example, in FIG. 1E and is specific for Claudin 18.2 and CD3. In some embodiments, the antibody is in an IgG-(scFv) format, which is, for example, illustrated in FIG. 1F and is specific for Claudin 18.2 and CD3. In some embodiments, the antibody specific for Claudin 18.2 and CD3 binds Claudin 18.2 and CD3 contemporaneously. Without being bound to any particular theory, the bispecific antibodywill bind to a tumor cell expressing Claudin 18.2 and an immune cell, such as a cytotoxic T cell, expressing CD3. By bringing the cells together, the T cell is activated and targets the tumor cell expressing Claudin 18.2 for destruction.

[0005] In one aspect, compositions are provided comprising an antibody in an scFv-Fab IgG antibody that binds to Claudin 18.2 and CD3. In some embodiments, the antibody comprises a first heavy chain, a second heavy chain, and a light chain, wherein(a) the first heavy chain is selected from:(i)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLWCLVKGFYPSD1AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, or(it)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4767), oran amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, or (iii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKG FYPSD1AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(b) the second heavy chain is selected from:(i)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLASPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4168), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), or(it)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVR QAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYY CARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVG DRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTI SSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRASPKSSDKTHTCPPCPAPEAAGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL PPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4169), o an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variantthereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSASPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3983), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAK1RPY1FK1AGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) the light chain is selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKPGQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3576), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0006] In some embodiments, an antibody is provided in an IgG-scFv antibody format that binds to Claudin 18.2 and CD3, wherein the antibody comprises:(a) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and (ii) the second heavy chain comprises:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFR QAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4778), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about98%, or about 99% identity thereto, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4803), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or avariant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4806); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11)or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, or(b) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKT1SKAKGQPREPQVYTLPPSREEMTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4767), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and (ii) the second heavy chain comprises:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFR QAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATY YCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGL VQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHID AWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK (SEQ ID NO: 4779), or an amino acid sequence having al least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4804), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about98%, or about 99% identity thereto, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and (C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVR QAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYY CARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVG DRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTI SSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGG GLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4807); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or avariant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and / or heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, or (c) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTF1SLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVR QAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVY YCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ IDNO: 4780), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK (SEQ ID NO: 4805), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4808); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKP GQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC S (SEQ ID NO: 3576), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or (iii) MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0007] In some embodiments, the antibody or composition comprising the same, is an antibody an IgG-(scFv)2antibody format that binds to Claudin 18.2 and CD3, wherein the antibody comprises:(a) a heavy chain selected from:(i)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQ PGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKD RFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTV SSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQ QKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN RWVFGGGTKLTVL (SEQ ID NO: 4769), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO:5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), (it) MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIY DTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITR (SEQ ID NO: 4770), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof,(iii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTTSRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS(SEQ ID NO: 4771), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, (iv)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPffiKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYS NRWVFGGGTKLTVL (SEQ ID NO: 4772), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), (v) MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQ APGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQrrR (SEQ ID NO: 4773), oran amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof.(vi)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 4774), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or avariant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof,(vii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT1SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 4775), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO:5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), (viii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRL SCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSK STAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGG GGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLA SGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITR (SEQ ID NO: 4776), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and(ix.)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRL SCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFT1SRDNAK NTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 4777), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKPGQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC S (SEQ ID NO: 3576), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCL1SDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS(SEQ ID NO: 3593), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ IDNO: 33) or a variant thereof, and(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQAPVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS(SEQ ID NO: 3817),an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or

[0008] a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof. In another aspect, the disclosure relates to a composition comprising an IgG-(scFv) antibody specific for Claudin 18.2 and CD3 comprising:(a) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTF1SLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQ APGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYC AKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYS NRWVFGGGTKLTVL (SEQ ID NO: 5202), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO:5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS(SEQ ID NO: 5205), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, or(b) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4767), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about98%, or about 99% identity thereto, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and (ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLV QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVK DRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYS NRWVFGGGTKLTVL (SEQ ID NO: 5203), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPV QAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGR FTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 5206) or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, or(c) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVR QAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, or(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVR QAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVY YCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 5204), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or avariant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGE1SSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRL SCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAK NTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 5207), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKP GQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC S (SEQ ID NO: 3576), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, and(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof

[0009] In certain embodiments of any of the above aspects, the Fc can be from IgG. In certain embodiments the IgG is human IgG. In certain embodiments, the human IgG is selected from IgGl, IgG2, IgG3, and IgG4.

[0010] In certain embodiments of any of the above aspects, the antibody is formed through a knob-in-hole interaction in the Fc region. In certain embodiments, the human IgG Fc comprises one or mutations to promote knob-in-hole interaction. In certain embodiments of any of the above aspects, the mutations are selected from (i) T366Y or T366W, and (ii) Y407T, Y407A, or Y407V. In certain embodiments of any of the above aspects, the mutations are selected from:(a) T366Y and Y407T or T366Y / F405A and T394W / Y407T in human IgGl, and(b) T366W / D399C and T366S / L368A / K392C / Y407V;T366W / K392C and T366S / L368A / D399C / Y407V;S354C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and S354C / T366S / L368A / Y407V;E356C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and E356C / T366S / L368A / Y407V;E357C / T366W and Y349C / T366S / L368A / Y407V; orY349C / T366W and E357C / T366S / L368A / Y407V, in human IgGl.

[0011] In certain embodiments of any of the above aspects, the human IgG Fc comprises one or mutations to reduce or eliminate the effector function of the Fc domains. In certain embodiments the mutations are L234A and L235A (LALA) substitutions in human IgGl.

[0012] In certain embodiments the human IgG Fc comprises one or mutations to stabilize a hinge region in the Fc domain. In certain embodiments, the mutation is S228P.

[0013] In another aspect, the disclosure relates to a composition comprising a tandem singlechain variable fragment (scFv) specific for Claudin 18.2 and CD3 comprising one or more of: (a) an amino acid sequence of:MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAM MWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAE DTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSGGGGSEVQLVESGGGLVQPG GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR1RSKYNNYATYYADSVKDRF nSRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS GGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQK PGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID: 4816), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or a variant thereof, the CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or a variant thereof, and the CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / ora variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, or(b) an amino acid sequence of:MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMG WVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDT AVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSGGGGSEVQLVES GGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATY YADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWG QGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGN YPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO. 4814), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or a variant thereof, the CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or a variant thereof, and the CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), wherein:any of the above sequences in subsections (a) optionally can have a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N or C-terminus and any of the above sequences optionally have the linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0014] In certain embodiments, the composition of any of the foregoing binds Claudin 18.2 and CD3 contemporaneously. In certain embodiments, the composition binds Claudin 18.2 with an affinity of less than 10 nM and with at least 100 fold greater affinity than Claudin 9, Claudin 3, and / or Claudin 4.

[0015] In certain embodiments, the first heavy chain, the second heavy chain, the light chain, and / or the single-chain variable fragment does not comprise amino acids 1-18 of its respective SEQ ID NO. In certain embodiments, the first heavy chain, the second heavy chain, the light chain, and / or the single-chain variable fragment does not comprise the amino acid sequence MKWVTFISLLFLFSSAYS (SEQ ID NO: 5356). In certain embodiments, the leader sequence, such as the amino acid sequence of SEQ ID NO: 5356, is removed during the expression of the antibody. The leader sequence of SEQ ID NO: 5356 can also be replaced with a different leader sequence to facilitate expression and / or secretion of the antibody. As provided for herein, in some embodiments, the antibody in a composition, such as a pharmaceutical composition, does not comprise a leader sequence, including, but not limited to the amino acid sequence of SEQ ID NO: 5356.

[0016] In another aspect, the disclosure relates to a pharmaceutical composition comprising an isolated antibody disclosed herein, or a nucleic acid molecule encoding the same. In certain embodiments, the pharmaceutical composition is an injectable pharmaceutical composition. In certain embodiments, the pharmaceutical composition is sterile. In certain embodiments, the pharmaceutical composition is pyrogen free.

[0017] In another aspect, the disclosure relates to a nucleic acid molecule encoding an antibody or an amino acid sequence as disclosed herein.

[0018] In another aspect, the disclosure relates to a vector comprising a nucleic acid molecule disclosed herein.

[0019] In another aspect, the disclosure relates to a cell comprising a nucleic acid molecule or vector as disclosure herein.

[0020] In another aspect, the disclosure relates to a method for modulating and / or targeting Claudin 18.2 and CD3 in a biological cell, comprising contacting the cell with a composition or pharmaceutical composition as disclosed herein.

[0021] In another aspect, the disclosure relates to a method for modulating Claudin 18.2 activity in a biological cell comprising contacting a cell expressing Claudin 18.2 with a composition or pharmaceutical composition as disclosed herein.

[0022] In another aspect, the disclosure relates to a method for inhibiting the function of Claudin 18.2 in a biological cell comprising contacting a cell expressing Claudin 18.2 with a composition or pharmaceutical composition as disclosed herein.

[0023] In another aspect, the disclosure relates to a method for treating or preventing cancer comprising administering an effective amount of the composition or pharmaceutical composition of any one of claims 1 to 52 as disclosed herein to a subject in need thereof.

[0024] In another aspect, the disclosure relates to a use of the composition or pharmaceutical composition as disclosed herein for the preparation of a medicament for the treatment of prevention of cancer.

[0025] In certain embodiments, the cancer is selected from one or more of basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; glioma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; malignant rhabdoid tumor; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphoma including Hodgkin’s and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom’s Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplantlymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses; edema (e.g. that associated with brain tumors); and Meigs’ syndrome.

[0026] In another aspect, the disclosure relates to an isolated antibody comprising one or more of the sequences disclosed herein.

[0027] In another aspect, the disclosure relates to a method of treating or preventing cancer comprising administering an effective amount of one or more nucleic acid molecules (e.g., RNA) described herein to a subject in need thereof.

[0028] In certain embodiments, the cancer is selected from one or more of basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; glioma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; malignant rhabdoid tumor; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphoma including Hodgkin’s and non-Hodgkin’s lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin’s lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom’s Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses; edema (e.g. that associated with brain tumors); and Meigs’ syndrome.

[0029] In certain embodiments, the nucleic acid molecule comprises a sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity to any one of SEQ ID NOs: 5329-5355.BRIEF DESCRIPTION OF THE DRAWINGS

[0030] FIGs. 1A-1F show images of illustrative bispecific formats, including a tandem scFv (FIG. 1A), a Hetero VH IgG (FIG. 1B), an scFv-Fab IgG (FIG. 1C), IgG-scFv (FIG. 1D), a IgG-(scFv)2(FIG. 1E), and IgG-(scFv) (FIG. 1F).

[0031] FIG. 2 is graph of the IM-16-44-09-B03-1CD3 antibody (Format 16 (scFv-Fab IgG)) binding to HEK 293F cells expressing human P2X3, CD3, or Claudin (CLDN) 18.2.

[0032] FIG. 3 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 - or CLDN 18.2-expressing cells (HEK293F) in the presence of IMC-16-C2 (control) or IM-16-44-09-B03-1CD3 antibodies (Format 16 (scFv-Fab IgG)). Percent (%) specific cytotoxicity was assessed 48 hours (48hr) later. Legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-16-44-09-B03-1CD3 on CLDN 18.1 (diamond), and IM-16-44-09-B03-1CD3 on CLDN 18.2 (triangle).

[0033] FIGs. 4A, 4B, 4C, 4D, and 4E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IMC-16-C2 or IM-16-44-09-B03-1CD3 antibodies. FIG. 4A illustrates the results for IL-2 production, FIG. 4B illustrates the results for IL-6 production, FIG. 4C illustrates the results for IL- 10 production, FIG. 4D illustrates the results for IFN-γ (INFgamma) production, and FIG. 4E illustrates the results for TNF-α (TNFalpha) production. Legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-16-44-09-B03-1CD3 on CLDN 18.1 (diamond), and IM-16-44-09-B03-1CD3 on CLDN 18.2 (triangle).

[0034] FIGs. 5A and 5B show size exclusion chromatography (SEC) and differential scanning fluorimetry (DSF) experimental results for the IM-16-44-09-B03-1CD3, IM-16-44- 09-B03-2CD3, and IM-16-44-09-B03-3CD3 antibodies.

[0035] FIG. 6 is graph of the IM-21-44-01 -E10-3CD3 antibody (Format 21 (IgG-(scFv)2)) binding to HEK 293F cells expressing human P2X3, CD3, or CLDN 18.2.

[0036] FIG. 7 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IMC-16-C2 (control) or IM-21 -44-01-E10-3CD3 (Format 21 (IgG- (scFv)2)). Percent (%) specific cytotoxicity was assessed 48 hours (48hr) later. Legend: IMC- 16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-21-44-01 -E10- 3CD3 on CLDN 18.1 (diamond), and IM-21-44-01-E10-3CD3 on CLDN 18.2 (triangle).

[0037] FIGs. 8A, 8B, 8C, 8D, and 8E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IMC-16-C2or IM-21-44-01-E10-3CD3. FIG. 8A illustrates the results for IL-2 production, FIG. 8B illustrates the results for IL-6 production, FIG. 8C illustrates the results for IL- 10 production, FIG. 8D illustrates the results for IFN-γ production, and FIG. 8E illustrates the results for TNF-α production. Legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-21-44-01-E10-3CD3 on CLDN 18.1 (diamond), and IM-21-44-01-E10-3CD3 on CLDN 18.2 (triangle).

[0038] FIGs. 9 A and 9B show size exclusion chromatography (SEC) and differential scanning fluorimetry (DSF) experimental results for IM-21 -44-01 -E10-1CD3 and IM-21-44- 01 -E10-3CD3 antibodies.

[0039] FIG. 10 is graph of the IM-21 -44-09-B03-3CD3 antibody (Format 21 (IgG-(scFv)2)) binding to HEK 293F cells expressing human P2X3, CD3, or CLDN 18.2.

[0040] FIG. 11 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IMC-16-C2 (control) or IM-21 -44-09-B03-3CD3 (Format 21 (IgG- (scFv)2)). Percent (%) specific cytotoxicity was assessed 48 hours (48hr) later.

[0041] FIGs. 12A, 12B, 12C, 12D, and 12E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IMC-16-C2 or IM-21-44-09-B03-3CD3. FIG. 12A illustrates the results for IL-2 production, FIG. 12B illustrates the results for IL-6 production, FIG. 12C illustrates the results for IL- 10 production, FIG. 12D illustrates the results for IFN-γ production, and FIG. 12E illustrates the results for TNF- a production. Legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-21 -44-09-B03-3CD3 on CLDN 18.1 (diamond), and IM-21-44- 09-B03-3CD3 on CLDN 18.2 (triangle).

[0042] FIGs. 13A and 13B show size exclusion chromatography (SEC) and differential scanning fluorimetry (DSF) experimental results for IM-21-44-09-B03-1CD3 and IM-21-44- 09-B03-3CD3 antibodies.

[0043] FIG. 14 is graph of the IM-2-44-05-H06-1CD3 antibody (Format 2 (tandem scFv)) binding to HEK 293F cells expressing human P2X3, CD3, or CLDN 18.2.

[0044] FIG. 15 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1- or CLDN 18.2-expressing HEK 293F cells in the presence of IMC-16-C2 (control) or IM-2-44-05-H06-1CD3 (Format 2 (tandem scFv)). Percent (%) specific cytotoxicity was assessed 48 hours (48hr) later. Legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-2-44-05-H06-1CD3 on CLDN 18.1 (diamond), and IM-2-44-05-H06-1CD3 on CLDN 18.2 (triangle).

[0045] FIGs. 16A, 16B, 16C, 16D, and 16E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IMC-16-C2 or IM-2-44-05-H06-1CD3. FIG. 16A illustrates the results for IL-2 production, FIG. 16B illustrates the results for IL-6 production, FIG. 16C illustrates the results for IL- 10 production, FIG. 16D illustrates the results for IFN-γ production, and FIG. 16E illustrates the results for TNF-α production. Legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-2-44-05-H06-1CD3 on CLDN 18.1 (diamond), and IM-2-44- 05-H06-1CD3 on CLDN 18.2 (triangle).

[0046] FIG. 17 is graph of the IM-2-44-09-B03-1CD3 antibody (Format 2 (tandem scFv)) binding to HEK 293F cells expressing human P2X3, CD3, or CLDN 18.2.

[0047] FIG. 18 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IMC-16-C2 (control) or IM-2-44-09-B03-1CD3 (Format 2 (tandem scFv)). Percent (%) specific cytotoxicity was assessed 48 hours (48hr) later. legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-2-44-09-B03-1CD3 on CLDN 18.1 (diamond), and 1M-2-44-09-B03-1CD3 on CLDN 18.2 (triangle).

[0048] FIGs. 19A, 19B, 19C, 19D, and 19E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IMC-16-C2 or IM-2-44-09-B03-1CD3. FIG. 19A illustrates the results for IL-2 production, FIG. 19B illustrates the results for IL-6 production, FIG. 19C illustrates the results for IL- 10 production, FIG. 19D illustrates the results for IFN-γ production, and FIG. 19E illustrates the results for TNF-α production. Legend: IMC-16-C2 on CLDN 18.1 (circles), IMC-16-C2 on CLDN 18.2 (squares), IM-2-44-09-B03-1CD3 on CLDN 18.1 (diamond), and IM-2-44- 09-B03-1CD3 on CLDN 18.2 (triangle).

[0049] FIG. 20 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IMC-16-C2 (control) antibodies.

[0050] FIG. 21 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM-42-44-09-B03-1CD3 (Format 42 EgG-(scFv)) antibodies. legend: IM- 42-44-09-B03-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0051] FIGs. 22A, 22B, 22C, 22D, and 22E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 09-B03-1CD3 antibodies. FIG. 22A illustrates the results for IL-2 production, FIG. 22Billustrates the results for IL-6 production, FIG. 22C illustrates the results for IL- 10 production, FIG. 22D illustrates the results for IFN-γ production, and FIG. 22E illustrates the results for TNF-α production. Legend: IM-42-44-09-B03-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0052] FIGs. 23A, 23B, 23C, 23D, and 23E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 09-B03-1CD3 antibodies. FIG. 23A illustrates the results for IL-2 production, FIG. 23B illustrates the results for IL-6 production, FIG. 23C illustrates the results for IL- 10 production, FIG. 23D illustrates the results for IFN-γ production, and FIG. 23E illustrates the results for TNF-α production.

[0053] FIG. 24 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM-42-44-09-B03-3CD3 antibodies (Format 42 IgG-(scFv)).

[0054] FIGs. 25A, 25B, 25C, 25D, and 25E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 09-B03-1CD3. FIG. 25A illustrates the results for IL-2 production, FIG. 25B illustrates the results for IL-6 production, FIG. 25C illustrates the results for IL- 10 production, FIG. 25D illustrates the results for IFN-γ production, and FIG. 25E illustrates the results for TNF-α production. legend: IM-42-44-09-B03-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0055] FIGs. 26A26B, 26C, 26D, and 26E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 09-B03-3CD3. FIG. 26A illustrates the results for IL-2 production, FIG. 26B illustrates the results for IL-6 production, FIG. 26C illustrates the results for IL- 10 production, FIG. 26D illustrates the results for IFN-γ production, and FIG. 26E illustrates the results for TNF-α production.

[0056] FIG. 27 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM-42-44-01-E10-1CD3 antibodies (Format 42 IgG-(scFv)).

[0057] FIGs. 28A, 28B, 28C, 28D, and 28E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 01 -E10-1 CD3. FIG. 28A illustrates the results for IL-2 production, FIG. 28B illustrates the results for IL-6 production, FIG. 28C illustrates the results for IL- 10 production, FIG. 28D illustrates the results for IFN-γ production, and FIG. 28E illustrates the results for TNF-αproduction. Legend: IM-42-44-01-E10-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0058] FIGs. 29A, 29B, 29C, 29D, and 29E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 01 -E10-1 CD3. FIG. 29A illustrates the results for IL-2 production, FIG. 29B illustrates the results for IL-6 production, FIG. 29C illustrates the results for IL- 10 production, FIG. 29D illustrates the results for IFN-γ production, and FIG. 29E illustrates the results for TNF-α production. Legend: IM-42-44-01 -E10-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0059] FIG. 30 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM -42-44-01 -E10-3CD3 antibodies (Format 42 IgG-(scFv)).

[0060] FIGs. 31A, 31B, 31C, 31D, and 31E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 01-E10-3CD3. FIG. 31A illustrates the results for IL-2 production, FIG. 31B illustrates the results for IL-6 production, FIG. 31C illustrates the results for IL- 10 production, FIG. 31D illustrates the results for IFN-γ production, and FIG. 31E illustrates the results for TNF-α production. Legend: IM-42-44-01 -E10-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0061] FIGs. 32A, 32B, 32C, 32D, and 32E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293 F cells with IM-42-44- 01 -E10-3CD3. FIG. 32A illustrates the results for IL-2 production, FIG. 32B illustrates the results for IL-6 production, FIG. 32C illustrates the results for IL- 10 production, FIG. 32D illustrates the results for IFN-γ production, and FIG. 32E illustrates the results for TNF-α production. Legend: IM-42-44-01-E10-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0062] FIG. 33 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM-42-44-05-H06-1CD3 antibodies (Format 42 IgG-(scFv)).

[0063] FIGs. 34A, 34B, 34C, 34D, and 34E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 05-H06-1CD3. FIG. 34A illustrates the results for IL-2 production, FIG. 34B illustrates the results for IL-6 production, FIG. 34C illustrates the results for IL- 10 production, FIG. 34D illustrates the results for IFN-γ production, and FIG. 34E illustrates the results for TNF-αproduction. Legend: IM-42-44-05 -H06-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0064] FIGs. 35A, 35B, 35C, 35D, and 35E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 05 -H06-1CD3. FIG. 35 A illustrates the results for IL-2 production, FIG. 35B illustrates the results for IL-6 production, FIG. 35C illustrates the results for IL- 10 production, FIG. 35D illustrates the results for IFN-γ production, and FIG. 35E illustrates the results for TNF-α production. Legend: IM-42-44-05-H06-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0065] FIG. 36 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM-42-44-05-H06-3CD3 antibodies (Format 42 IgG-(scFv)).

[0066] FIGs. 37A, 37B, 37C, 37D, and 37E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-42-44- 05-H06-3CD3. FIG. 37 A illustrates the results for IL-2 production, FIG. 37B illustrates the results for IL-6 production, FIG. 37C illustrates the results for IL- 10 production, FIG. 37D illustrates the results for IFN-γ production, and FIG. 37E illustrates the results for TNF-α production. Legend: IM-42-44-05-H06-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0067] FIGs. 38A, 38B, 38C, 38D, and 38E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293 F cells with IM-42-44- 05-H06-3CD3. FIG. 38A illustrates the results for IL-2 production, FIG. 38B illustrates the results for IL-6 production, FIG. 38C illustrates the results for IL- 10 production, FIG. 38D illustrates the results for IFN-γ production, and FIG. 38E illustrates the results for TNF-α production. Legend: IM-42-44-05-H06-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0068] FIG. 39 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM -21 -44-09-B03-3CD3 antibodies (Format 21 (IgG-(scFv)2)).

[0069] FIGs. 40A, 40B, 40C, 40D, and 40E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-21 -44- 09-B03-3CD3 antibodies. FIG. 40A illustrates the results for IL-2 production, FIG. 40B illustrates the results for IL-6 production, FIG. 40C illustrates the results for IL- 10 production, FIG. 40D illustrates the results for IFN-γ production, and FIG. 40E illustratesthe results for TNF-α production. Legend: IM-21-44-09-B03-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0070] FIGs. 41A, 41B, 41C, 41D, and 41E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-21 -44- 09-B03-3CD3. FIG. 41A illustrates the results for IL-2 production, FIG. 41B illustrates the results for IL-6 production, FIG. 41C illustrates the results for IL- 10 production, FIG. 4 ID illustrates the results for IFN-γ production, and FIG. 41E illustrates the results for TNF-α production. Legend: IM-21 -44-09-B03-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0071] FIG. 42 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM-21-44-01-E10-3CD3 antibodies (Format 21 (IgG-(scFv)2)).

[0072] FIGs. 43A, 43B, 43C, 43D, and 43E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-21-44- 01 -E10-3CD3 antibodies. FIG. 43 A illustrates the results for IL-2 production, FIG. 43B illustrates the results for IL-6 production, FIG. 43C illustrates the results for IL- 10 production, FIG. 43D illustrates the results for IFN-γ production, and FIG. 43E illustrates the results for TNF-α production. Legend: IM-21-44-01-E10-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0073] FIGs. 44A, 44B, 44C, 44D, and 44E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293 F cells with IM-21-44- 01 -E10-3CD3. FIG. 44A illustrates the results for IL-2 production, FIG. 44B illustrates the results for IL-6 production, FIG. 44C illustrates the results for IL- 10 production, FIG. 44D illustrates the results for IFN-γ production, and FIG. 44E illustrates the results for TNF-α production. Legend: IM-21-44-01-E10-3CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0074] FIG. 45 is a graph of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of IM-2-44-05-H06-1CD3 antibodies (Format 2 (tandem scFv)).

[0075] FIGs. 46A, 46B, 46C, 46D, and 46E show cytokines produced 24hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-2-44- 05-H06-1CD3 antibodies. FIG. 46A illustrates the results for IL-2 production, FIG. 46B illustrates the results for IL-6 production, FIG. 46C illustrates the results for IL- 10 production, FIG. 46D illustrates the results for IFN-γ production, and FIG. 46E illustratesthe results for TNF-α production. Legend: IM-2-44-05-H06-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0076] FIGs. 47A, 47B, 47C, 47D, and 47E show cytokines produced 48hr after co-culturing human PBMCs and human CLDN 18.1- or 18.2-expressing HEK 293F cells with IM-2-44- 05 -H06-1CD3. FIG. 47 A illustrates the results for IL-2 production, FIG. 47B illustrates the results for IL-6 production, FIG. 47C illustrates the results for IL- 10 production, FIG. 47D illustrates the results for IFN-γ production, and FIG. 47E illustrates the results for TNF-a production. Legend: IM-2-44-05-H06-1CD3 on CLDN 18.1 (circles) and CLDN 18.2 (triangles).

[0077] FIG. 48 is a set of graphs of T-cell dependent cellular cytotoxicity experiments where human T-cells were co-cultured with human CLDN 18.1 or CLDN 18.2 expressing HEK 293F cells in the presence of mRNA encoding IM-2-44-09B03-1CD3 or IM-16-44-09B03- 1CD3 antibodies.DETAILED DESCRIPTIONAntibodies Specific for Claudin 18.2 and CD3

[0078] The present embodiments are based, in part, on the surprising discovery of antibodies specific for Claudin 18.2 and CD3. The present disclosure describes, in part, the isolation and characterization of antibodies, antibody fragments, and antibody variants specific for Claudin 18.2 and CD3. In some embodiments, the antibody is a tandem single-chain variable fragment (scFv) specific for Claudin 18.2 and CD3, which is for example, illustrated in FIG. 1A. In some embodiments, the antibody is a hetero VH IgG, such as illustrated in FIG. 1B and specific for Claudin 18.2 and CD3. In some embodiments, the antibody is an scFv-Fab IgG antibody format, which, for example, is illustrated in FIG. 1C and specifically binds to Claudin 18.2 and CD3. In some embodiments, the antibody is an IgG-scFv format, which, for example, is illustrated in FIG. 1D and specifically binds to Claudin 18.2 and CD3. In some embodiments, the antibody is an IgG-(scFv)2antibody format, which, for example, is illustrated in FIG. 1E and specifically binds to Claudin 18.2 and CD3. In some embodiments, the antibody is a IgG-(scFv) format, which, for example, is illustrated in FIG. 1F and specifically binds to Claudin 18.2 and CD3. In some embodiments, the antibody specific for Claudin 18.2 and CD3 binds Claudin 18.2 and CD3 contemporaneously. Without being bound to any particular theory, the bispecific antibody will bind to a tumor cell expressing Claudin 18.2 and an immune cell, such as a cytotoxic T cell, expressing CD3. By bringing the cells together, the T cell is activated and targets the tumor cell expressing Claudin 18.2 for destruction.

[0079] For example, in some embodiments, the antibody specific for Claudin 18.2 and CD3 is a tandem scFv. An exemplary tandem scFv is shown schematically in FIG. 1A. A tandem scFv antibody specific for Claudin 18.2 and CD3 can be selected from an amino acid sequence of SEQ ID NO: 4816 and SEQ ID NO: 4814, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto.

[0080] In some embodiments, the antibody specific for Claudin 18.2 and CD3 is a hetero VH IgG antibody comprising two heavy chains and two light chains. The light chains optionally can comprise the same amino acid sequence. An exemplary hetero VH IgG is shown schematically in FIG. 1B. A hetero VH IgG antibody specific for Claudin 18.2 and CD3 can comprise a first heavy chain having an amino acid sequence of SEQ ID NO: 3869, SEQ ID NO: 4767, or SEQ ID NO: 4768 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a second heavy chain having an amino acid sequence comprising the heavy chain CDRs of any anti-CD3 scFv provided herein. In some embodiments, the light chain comprises an amino acid sequence of SEQ ID NO: 3593, SEQ ID NO: 3576, or SEQ ID NO: 3817, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto.

[0081] In some embodiments, the antibody specific for Claudin 18.2 and CD3 is an scFv-Fab IgG antibody comprising a first heavy chain, a second heavy chain, and a light chain. An exemplary scFv-Fab IgG antibody is shown schematically in FIG. 1C. An antibody specific for Claudin 18.2 and CD3 can comprise a first heavy chain having an amino acid sequence of SEQ ID NO: 3869, SEQ ID NO: 4767, or SEQ ID NO: 4768, a second heavy chain having an amino acid sequence of SEQ ID NO: 4168, SEQ ID NO: 4169, or SEQ ID NO: 3983, and a light chain having an amino acid sequence of SEQ ID NO: 3593, SEQ ID NO: 3576, or SEQ ID NO: 3817. In some embodiments, the first heavy chain comprises an amino acid sequence of SEQ ID NO: 3869, SEQ ID NO: 4767, or SEQ ID NO: 4768, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In some embodiments, the second heavy comprises an amino acid sequence of SEQ ID NO: 4168, SEQ ID NO: 4169, or SEQ ID NO: 3983, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In some embodiments, the light chain comprises an amino acid sequence of SEQ ID NO: 3593, SEQ ID NO: 3576, or SEQ ID NO: 3817, or an amino acid sequencehaving at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto.

[0082] In some embodiments, the antibody specific for Claudin 18.2 and CD3 is a IgG-scFv antibody comprising two heavy chains (a first and second heavy chain) and two light chains. In some embodiments, the two heavy chains comprising amino acid sequences that are different from each other, and the two light chains comprise amino acid sequences that are identical. An exemplary IgG-scFv is shown schematically in FIG. 1D. In some embodiments, the first heavy chain has an amino acid sequence of SEQ ID NO: 3869, SEQ ID NO: 4767, or SEQ ID NO: 4768 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In some embodiments, the second heavy chain has an amino acid sequence of SEQ ID NO: 4778, SEQ ID NO: 4779, SEQ ID NO: 4780, SEQ ID NO: 4803, SEQ ID NO: 4804, SEQ ID NO: 4805, SEQ ID NO: 4806, SEQ ID NO: 4807, SEQ ID NO: 4808 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In certain embodiments, the antibody specific for Claudin 18.2 and CD3 comprises a first heavy chain having an amino acid sequence of SEQ ID NO: 3869 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a second heavy chain selected from SEQ ID NO: 4778, SEQ ID NO: 4803, and SEQ ID NO: 4806 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto In certain embodiments, the antibody specific for Claudin 18.2 and CD3 comprises a first heavy chain having an amino acid sequence of SEQ ID NO: 4767 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a second heavy chain selected from SEQ ID NO: 4779, SEQ ID NO: 4804, and SEQ ID NO: 4807 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In certain embodiments, the antibody specific for Claudin 18.2 and CD3 comprises a first heavy chain having an amino acid sequence of SEQ ID NO: 4768 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a second heavy chain selected from SEQ ID NO: 4780, SEQ ID NO: 4805, and SEQ ID NO: 4808 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. The two light chains can be selected from SEQ ID NO: 3593, SEQ ID NO: 3576, and SEQ ID NO: 3817 or an amino acid sequence having at least about 90%,about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. The two light chains can comprise the same amino acid sequence.

[0083] In some embodiments, the antibody specific for Claudin 18.2 and CD3 is an IgG- (SCFV)2antibody comprising two heavy chains and two light chains, wherein the heavy chains are identical to each other and the light chains are identical to each other. An exemplary IgG- (SCFV)2antibody is shown schematically in FIG. 1E. In some embodiments, the antibody comprises a heavy chain selected comprising an amino acid sequence of SEQ ID NO: 4769, SEQ ID NO: 4770, SEQ ID NO: 4771, SEQ ID NO: 4772, SEQ ID NO: 4773, SEQ ID NO: 4774, SEQ ID NO: 4775, SEQ ID NO: 4776, or SEQ ID NO: 4777, and a light chain selected from an amino acid sequence of SEQ ID NO: 3593, SEQ ID NO: 3576, or SEQ ID NO: 3817. In some embodiments, the heavy chain comprises an amino acid sequence of SEQ ID NO: 4769, SEQ ID NO: 4770, SEQ ID NO: 4771, SEQ ID NO: 4772, SEQ ID NO: 4773, SEQ ID NO: 4774, SEQ ID NO: 4775, SEQ ID NO: 4776, or SEQ ID NO: 4777,, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In some embodiments, the light chain comprises an amino acid sequence of SEQ ID NO: 3593, SEQ ID NO: 3576, or SEQ ID NO: 3817, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto.

[0084] In some embodiments, the antibody specific for Claudin 18.2 and CD3 is a IgG- (scFv) antibody comprising two heavy chains (a first and second heavy chain) and two light chains. In some embodiments, the two heavy chains comprising amino acid sequences that are different from each other, and the two light chains comprise amino acid sequences that are identical. An exemplary IgG-scFv is shown schematically in FIG. 1E. In some embodiments, the first heavy chain has an amino acid sequence of SEQ ID NO: 3869, SEQ ID NO: 4767, or SEQ ID NO: 4768, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In some embodiments, the second heavy chain has an amino acid sequence of SEQ ID NO: 5202, SEQ ID NO: 5205, SEQ ID NO: 5203, SEQ ID NO: 5206, SEQ ID NO: 5204, or SEQ ID NO: 5207, or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In some embodiments, the two light chains each have an amino acid sequence comprising SEQ ID NO: 3593, SEQ ID NO: 3576, or SEQ ID NO: 3817 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. The two light chains can comprise the same amino acid sequence. In certain embodiments, the antibody specific forClaudin 18.2 and CD3 comprises a first heavy chain having an amino acid sequence of SEQ ID NO: 3869 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, a second heavy chain having an amino acid sequence of SEQ ID NO: 5202 or 5205 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a light chain (e.g., a first and second light chain) having an amino acid sequence of SEQ ID NO: 3593 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In certain embodiments, the antibody specific for Claudin 18.2 and CD3 comprises a first heavy chain having an amino acid sequence of SEQ ID NO: 4767 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, a second heavy chain having an amino acid sequence of SEQ ID NO: 5203 or SEQ ID NO: 5206 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a light chain (e.g., a first and second light chain) having an amino acid sequence of SEQ ID NO: 3576 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto. In certain embodiments, the antibody specific for Claudin 18.2 and CD3 comprises a first heavy chain having an amino acid sequence of SEQ ID NO: 4768 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a second heavy chain having an amino acid sequence of SEQ ID NO: 5204 or 5207 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, and a light chain having an amino acid sequence of SEQ ID NO: 3817 or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto.

[0085] In various embodiments, the antibody (e.g., a tandem scFv antibody, a hetero VH IgG antibody, an scFv-Fab IgG antibody, an IgG-scFv antibody, IgG-(scFv)? antibody, and a IgG- (scFv) antibody), or fragment thereof, or variant thereof, may comprise an amino acid sequence having one or more amino acid mutations (e.g., substitutions or deletions) relative to any of the sequences disclosed herein. In some embodiments, the one or more amino acid mutations may be independently selected from substitutions, insertions, deletions, and truncations. In embodiments, the antibody (e.g., a tandem scFv antibody, a hetero VH IgG antibody, an scFv-Fab IgG antibody, an IgG-scFv antibody, IgG-(scFv)2antibody, and a IgG- (scFv) antibody), or fragment thereof, or variant thereof, comprises a sequence that has about1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more amino acid mutations with respect to any one of the amino acid sequences disclosed herein.

[0086] In various embodiments, the antibody or antibody format (e.g. , a tandem scFv antibody, a hetero VH IgG antibody, an scFv-Fab IgG antibody, an IgG-scFv antibody, IgG- (SCFV)2antibody, and a IgG-(scFv) antibody), or fragment thereof, or variant thereof, may comprise an amino acid sequence having al least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% sequence homology to the amino acid sequences disclosed herein.

[0087] In various embodiments, the present invention provides for variants or fragments comprising any of the sequences described herein, for instance, a sequence having at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%) sequence identity with any of the sequences disclosed herein.

[0088] In some embodiments, variants are those that have conservative amino acid substitutions made at one or more predicted non-essential amino acid residues. For example, a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.

[0089] In embodiments, the amino acid mutations are amino acid substitutions, and may include conservative and / or non-conservative substitutions.

[0090] “Conservative substitutions” may be made, for instance, on the basis of similarity in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and / or the amphipathic nature of the amino acid residues involved. The 20 naturally occurring amino acids can be grouped into the following six standard amino acid groups: (1) hydrophobic: Met, Ala, Vai, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; Asn, Gin; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe.

[0091] As used herein, “conservative substitutions” are defined as exchanges of an amino acid by another amino acid listed within the same group of the six standard amino acid groups shown above. For example, the exchange of Asp by Glu retains one negative charge in the so modified polypeptide. In addition, glycine and proline may be substituted for one another based on their ability to disrupt α-helices.

[0092] As used herein, “non-conservative substitutions” are defined as exchanges of an amino acid by another amino acid listed in a different group of the six standard amino acid groups (1) to (6) shown above.

[0093] As disclosed herein, the term “antibody” refers to a broad sense and includes immunoglobulin or antibody molecules including polyclonal antibodies, monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies and antibody fragments, such as ScFv (PLOS Biology | D01:10.1371 / joumal.pbio.l002344 January 6, 2016, which is hereby incorporated by reference in its entirety).

[0094] In general, antibodies are proteins or polypeptides that exhibit binding specificity to a specific antigen. Intact antibodies are heterotetrameric glycoproteins, composed of two identical light chains and two identical heavy chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain and the light chain variable domain is aligned with the variable domain of the heavy chain. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains.Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub-classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4.

[0095] As disclosed herein, the term “antibody fragment” refers to an intact antibody, generally the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2 and Fv fragments, diabodies, single chain antibody molecules and multispecific antibodies formed from at least two intact antibodies or fragments thereof.

[0096] As disclosed herein, the term “antigen” refers to any molecule that has the ability to generate antibodies either directly or indirectly.

[0097] As disclosed herein, the term “specific binding” or “immunospecific binding” or “binds immunospecifically” refers to antibody binding to a predetermined antigen (e.g., Claudin 18.2) or epitope present on the antigen. In some embodiments, the antibody binds with a dissociation constant (KD) of about 10-10M or less, of about 10-9M or less, of about 10-8M or less, of about 10-7M or less, of about 10-6M or less, of about 10-5M or less, and binds to the predetermined antigen with a KD that is at least two-fold less than its KD for binding to a non-specific antigen (e.g., BSA, casein, or another non-specific polypeptide) other than the predetermined antigen. The phrases “an antibody recognizing Claudin 18.2” and “an antibody specific for Claudin 18.2” are used interchangeably herein with the term “an antibody which binds immunospecifically to Claudin 18.2.” Reference in the present disclosure may be made to Claudin 18.2. In some embodiments, the antibody is specific for Claudin 18.2 and does not specifically bind to Claudin 3, Claudin 4, and / or Claudin 9.

[0098] “CDRs” are referred to as the complementarity determining region amino acid sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light chains. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 4th ed., U.S. Department of Health and Human Services, National Institutes of Health (1987). There are three heavy chain and three light chain CDRs or CDR regions in the variable portion of an immunoglobulin. Thus, “CDRs” as used herein refers to all three heavy chain CDRs, or all three light chain CDRs or both all heavy and all light chain CDRs, if appropriate.

[0099] Each variable region comprises three hypervariable regions also known as complementarity determining regions (CDRs) flanked by four relatively conserved framework regions (FRs). The three CDRs, referred to as CDR1, CDR2, and CDR3, contribute to the antibody binding specificity, as the CDRs provide the majority of contact residues for the binding of the antibody to the antigen or epitope. CDRs of interest can be derived from donor antibody variable heavy and light chain sequences, and include analogs of the naturally occurring CDRs, which analogs also share or retain the same antigen binding specificity and / or neutralizing ability as the donor antibody from which they were derived. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody.

[0100] CDRs are based on sequence variability (Wu and Kabat, J. Exp. Med. 132:211-250, 1970). There are six CDRs— three in the variable heavy chain, or VH, and are typically designated H-CDR1, H-CDR2, and H-CDR3, and three CDRs in the variable light chain, orVL, and are typically designated L-CDR1 , L-CDR2, and L-CDR3 (Kabat et al. , Sequences of Proteins of Immunological Interest, Sth Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991). “Hypervariable region”, “HVR”, or “HV” refer to the regions of an antibody variable domain which are variable in structure as defined by Chothia and Lesk (Chothia and Lesk, Mol. Biol. 196:901-917, 1987). There are six HVRs, three in VH (Hl, H2, H3) and three in VL (LI, L2, L3). Chothia and Lesk refer to structurally conserved HVs as “canonical structures.” Another method of describing the regions that form the antigen-binding site has been proposed by Lefranc (Lefranc et al., Developmental & Comparative Immunology 27:55-77, 2003) based on the comparison of V domains from immunoglobulins and T-cell receptors (Lefranc et al., Developmental & Comparative Immunology 27:55-77, 2003). The antigen-binding site can also be delineated based on “Specificity Determining Residue Usage (SDRU)", according to Almagro (Almagro, Mol. Recognit. 17:132-43, 2004), where SDRU refers to amino acid residues of an immunoglobulin that are directly involved in antigen contact.

[0101] An “isolated antibody,” as used herein, refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds Claudin 18.2 is substantially free of antibodies that specifically bind antigens other than Claudin 18.2). Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals. An isolated antibody can also be sterile or pyrogen free or formulated as injectable pharmaceutical as described herein.

[0102] In some embodiments, the source for the DNA encoding a non-human antibody include cell lines which produce antibody, such as hybrid cell lines commonly known as hybridomas.

[0103] In some embodiments, the antibody or antibody fragment or variant disclosed herein (e.g., a tandem scFv antibody, a hetero VH IgG antibody, an scFv-Fab IgG antibody, an IgG- scFv antibody, IgG-(scFv)2antibody, and a IgG-(scFv) antibody) comprises a CD3 engager. In some embodiments, the CD3 engager can be selected from muOKT3, huOKT3, huSP34, huUCHTl and a CD3 nanobody (VHH).

[0104] In some embodiments, the antibody or antibody fragment or variant is an antibody provided in TABLES 1-5, or an antibody fragment or variant thereof having at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about96%, or al least about 97%, or al least about 98%, or al least about 99%) sequence identity with an antibody disclosed therein.TABLE 1: Tandem scFvsTABLE 2: scFv-Fab IgGTABLE 3: IgG-scFvTABLE 4: IgG-(scFv)2TABLE 5: IgG-(scFv)

[0105] In certain embodiments, the leader sequence, such as the amino acid sequence of SEQ ID NO: 5356, is removed during the expression of the antibody. The leader sequence of SEQ ID NO: 5356 can also be replaced with a different leader sequence to facilitate expression and / or secretion of the antibody. As provided for herein, in some embodiments, the antibody in a composition, such as a pharmaceutical composition, does not comprise a leader sequence, including, but not limited to the amino acid sequence of SEQ ID NO: 5356.

[0106] In some embodiments, the antibody or antibody fragment or variant is an antibody provided in TABLES 1-5, wherein the first heavy chain, the second heavy chain, the light chain, and / or the single-chain variable fragment does not comprise the signal sequence of amino acids 1-18 relative to the respective SEQ ID NO (e.g., in some embodiments, a fragment of the antibody or variant comprises a sequence provided in TABLE A). In some embodiments, the antibody or antibody fragment or variant is an antibody provided in TABLES 1-5, wherein the first heavy chain, the second heavy chain, the light chain, and / or the single-chain variable fragment does not comprise the amino acid sequence MKWVTFISLLFLFSSAYS (SEQ ID NO: 5356) (e.g., in some embodiments, a fragment of the antibody or variant comprises a sequence provided in TABLE A).TABLE A: Antibody Components Described in TABLES 1-5 Not Comprising the Amino Acid Sequence MKWVTFISLLFLFSSAYS (SEQ ID NO: 5356)

[0107] In one aspect, the disclosure relates to a composition comprising an scFv-Fab IgG antibody specific for Claudin 18.2 and CD3 comprising a first heavy chain, a second heavy chain, and a light chain, wherein:(a) the first heavy chain is selected from:(i)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQ APGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYC AKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, or(it)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4767), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, or (iii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVR QAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVY YCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(b) the second heavy chain is selected from:(i)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLASPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4168), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), or(ii)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRASPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4169), oan amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFR QAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATY YCAAK1RPY1FK1AGQYDYWGQGTQVTVSSASPKSSDKTHTCPPCPAPEAAGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3983), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(c) the light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKPGQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC S (SEQ ID NO: 3576), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ IDNO: 33) or a variant thereof, or(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS(SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQAPVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, ora light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or wherein: any of the above sequences in subsections (a) optionally can have a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N or C-terminus and any of the above sequences optionally have the linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0108] In another aspect, the disclosure relates to a composition comprising an IgG-scFv antibody specific for Claudin 18.2 and CD3 comprising:(a) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTF1SLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQ APGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYC AKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4778), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK (SEQ ID NO: 4803), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO:5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTJTCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK (SEQ ID NO: 4806); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, or(b) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQ APGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4767), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or avariant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence isCAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK (SEQ ID NO: 4779), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, (B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVR QAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4804), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNS Y1SYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and (C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVR QAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYY CARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVG DRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTI SSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGG GLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4807); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and / or heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, or (c) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVR QAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVY YCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFR QAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATY YCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGL VQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKG RAT1SRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADS1DAWGQGTLVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4780), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23)or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA(SEQ ID NO: 24) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFS GSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK (SEQ ID NO: 4805), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4808); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKP GQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC S (SEQ ID NO: 3576), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTAR1TCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), oran amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, wherein: any of the above sequences in subsections (a) optionally can have a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N or C-terminus and any of the above sequences optionally have the linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0109] In another aspect, the disclosure relates to a composition comprising an IgG-(scFv)2antibody specific for Claudin 18.2 and CD3 comprising:(a) a heavy chain selected from:(i)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQ APGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYC AKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 4769), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about98%, or about 99% identity thereto, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), (ii) MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQ APGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYC AKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQ PGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFT ISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSG GGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIY DTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITR (SEQ ID NO: 4770), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variantthereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof,(iii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS(SEQ ID NO: 4771), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSS Y GMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or avariant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, (iv)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQ APGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPffiKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLV QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVK DRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYS NRWVFGGGTKLTVL (SEQ ID NO: 4772), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9),(v)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRF TISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGS GGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWI YDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT R (SEQ ID NO: 4773), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof.(vi)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS(SEQ ID NO: 4774), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, (vii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGG SGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQA PRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFG GGTKLTVL (SEQ ID NO: 4775), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), (viii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITR (SEQ ID NO: 4776), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and(ix.)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAK NTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 4777), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKP GQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCL1SDFYPGAVTVAWKADSSP VKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3576), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQAPVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3593), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, ora light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, and(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or wherein: any of the above sequences in subsections (a) optionally can have a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N or C-terminus and any of the above sequences optionally have the linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0110] In another aspect, the disclosure relates to a composition comprising an IgG-(scFv) antibody specific for Claudin 18.2 and CD3 comprising:(a) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQ APGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYC AKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQ APGKGLEWVAAITRDSSTNYGAAVKGRAT1SRDNSKNTLYLQMNSLRAEDTAVYYC AKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 5202), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variantthereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS(SEQ ID NO: 5205), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or avariant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, or(b) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQ APGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4767), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and (ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYS NRWVFGGGTKLTVL (SEQ ID NO: 5203), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 5206) oran amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, or(c) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVR QAPGKGLEWVGE1SSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVY YCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, or(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVR QAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFG GGTKLTVL (SEQ ID NO: 5204), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRL SCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAK NTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 5207), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKP GQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIF GGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP VKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC S (SEQ ID NO: 3576), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and thelight chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQAPVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKA GVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG(SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, and(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, wherein: any of the above sequences in subsections (a) optionally can have a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N or C-terminus andany of the above sequences optionally have the linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0111] In another aspect, the disclosure relates to a composition comprising a tandem single-chain variable fragment (scFv) specific for Claudin 18.2 and CD3 comprising one or more of:(a) an amino acid sequence of:MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQ APVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGG GTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAM MWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAE DTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSGGGGSEVQLVESGGGLVQPG GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRF TISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS GGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQK PGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNR WVFGGGTKLTVL (SEQ ID: 4816), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or a variant thereof, the CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or a variant thereof, and the CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, or(b) an amino acid sequence of:MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQKPGQ APVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGG TKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMG WVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDT AVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSGGGGSEVQLVES GGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATY YADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWG QGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGN YPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO. 4814), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or a variant thereof, the CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or a variant thereof, and the CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or a variant thereof, and / or a variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), wherein: any of the above sequences in subsections (a) optionally can have a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N or C-terminus and any of the above sequences optionally have the linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

[0112] In some embodiments, the antibody or antibody fragment or variant disclosed herein (e.g., a tandem scFv antibody, a hetero VH IgG antibody, an scFv-Fab IgG antibody, an IgG- scFv antibody, IgG-(scFv)z antibody, and a IgG-(scFv) antibody) comprise a linker having one or more glycines and serines replaced with a functionally equivalent variation thereof. In some embodiments, the linker is identified in the underlined text above. For example, in some embodiments, the linker is selected from the amino acid sequence of GGGGSGGGGSGGGGS (SEQ ID NO: 50), GGGGS (SEQ ID NO: 51), GGSGGSGGSGGSGGVD (SEQ ID NO: 52), and GKPGSGKPGSGKPGSGKPGS (SEQ ID NO: 53).

[0113] In some embodiments, the linker may be derived from naturally-occurring multidomain proteins or are empirical linkers as described, for example, in Chichili et al., (2013), Protein Sci. 22(2): 153- 167, Chen et al., (2013), Adv Drug Deliv Rev. 65(10): 1357-1369, the entire contents of which are hereby incorporated by reference. In some embodiments, the linker may be designed using linker designing databases and computer programs such as those described in Chen et al., (2013), Adv Drug Deliv Rev. 65(10):1357-1369 and Crasto et. al., (2000), Protein Eng. 13(5):309-312, the entire contents of which are hereby incorporated by reference. In some embodiments, the linker is as provided in Moore et al., (2019), Methods 154:38-50, the entire contents of which are hereby incorporated by reference.

[0114] In some embodiments, the linker is a polypeptide. In some embodiments, the linker is less than about 100 amino acids long. For example, the linker may be less than about 100, about 95, about 90, about 85, about 80, about 75, about 70, about 65, about 60, about 55, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, or about 2 amino acids long. In some embodiments, the linker is flexible. In another embodiment, the linker is rigid. In various embodiments, the linker is substantially comprised of glycine and serine residues (e.g. about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97% glycines and serines).

[0115] Additional illustrative linkers include, but are not limited to, linkers having the sequence LE, GGGGS (SEQ ID NO: 51), (GGGGS)n(n=1-4) (SEQ ID NO: 5264),(Gly)8(SEQ ID NO: 5265), (Gly)6(SEQ ID NO: 5266), (EAAAK)n(n=1-3) (SEQ ID NO: 5267), A(EAAAK)nA (n = 2-5) (SEQ ID NO: 5268), AEAAAKEAAAKA (SEQ ID NO: 5269), A(EAAAK)4ALEA(EAAAK)4A (SEQ ID NO: 5270), PAPAP (SEQ ID NO: 5271), KESGSVSSEQLAQFRSLD (SEQ ID NO: 5272), EGKSSGSGSESKST (SEQ ID NO:5273), GSAGSAAGSGEF (SEQ ID NO: 5274), and (XP)n, with X designating any amino acid, e.g., Ala, Lys, or Glu.

[0116] In various embodiments, the linker may be functional. For example, without limitation, the linker may function to improve the folding and / or stability, improve the expression, improve the pharmacokinetics, and / or improve the bioactivity of the present compositions. In another example, the linker may function to target the compositions to a particular cell type or location.

[0117] As used herein, the term constant domain refers to the Fc domain. The constant domains exemplified above are optional embodiments and other constant domains can be substituted for the constant domains described herein.

[0118] In some embodiments, the Fc is from IgG. In some embodiments, the IgG is human IgG. In some embodiments, the human IgG is selected from IgGl, IgG2, IgG3, and IgG4.

[0119] In some embodiments, the antibody is formed through a knob-in-hole interaction in the Fc region. In some embodiments, the human IgG Fc comprises one or mutations to promote knob-in-hole interaction. In some embodiments, the mutations are selected from (i) T366Y or T366W, and (ii) Y407T, Y407A, or Y407V. In some embodiments, the mutations are:(a) T366Y and Y407T or T366Y / F405A and T394W / Y407T in human IgGl or(b) T366W / D399C and T366S / L368A / K392C / Y407V;T366W / K392C and T366S / L368A / D399C / Y407V;S354C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and S354C / T366S / L368A / Y407V;E356C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and E356C / T366S / L368A / Y407V;E357C / T366W and Y349C / T366S / L368A / Y407V; or Y349C / T366W and E357C / T366S / L368A / Y407V, in human IgGl.

[0120] In some embodiments, the human IgG Fc comprises one or mutations to reduce or eliminate the effector function of the Fc domains. In some embodiments, the mutations are L234A and L235A (LALA) substitutions in human IgGl. In some embodiments, the human IgG Fc comprises one or mutations to stabilize a hinge region in the Fc domain. In some embodiments, the mutation is S228P.

[0121] In some embodiments, the composition binds Claudin 18.2 and CD3 contemporaneously.

[0122] In some embodiments, the composition binds Claudin 18.2 with an affinity of less than 10 nM and with at least 100 fold greater affinity than Claudin 9, Claudin 3, and / or Claudin 4.

[0123] In any of the embodiments disclosed herein, the composition induces cellular cytotoxicity.

[0124] In any of the embodiments disclosed herein, the composition induces T cell cytotoxicity.

[0125] In any of the embodiments disclosed herein, the composition induces T cell dependent cytotoxicity.

[0126] In any of the embodiments disclosed herein, the composition increases the expression and / or the release of one or more cytokines. In any of the embodiments disclosed herein, the composition increases the expression and / or the release of one or more cytokines selected from IL-2, IL-6, IL-10, IFN-γ, and TNF-α.

[0127] In some embodiments, disclosed herein is a pharmaceutical composition comprising an isolated antibody of any one of the preceding embodiments, or a nucleic acid molecule encoding the same. In some embodiments, the composition is an injectable pharmaceutical composition. In some embodiments, the composition is sterile. In some embodiments, the composition is pyrogen free.

[0128] In addition, this document also provides pharmaceutical compositions that composition as described herein, in combination with a pharmaceutically acceptable carrier. A “pharmaceutically acceptable carrier” (also referred to as an “excipient” or a “carrier”) is a pharmaceutically acceptable solvent, suspending agent, stabilizing agent, or any other pharmacologically inert vehicle for delivering one or more therapeutic compounds to a subject (e.g., a mammal, such as a human, non-human primate, dog, cat, sheep, pig, horse, cow, mouse, rat, or rabbit), which is nontoxic to the cell or subject being exposed thereto at the dosages and concentrations employed. Pharmaceutically acceptable carriers can be liquid or solid, and can be selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, and other pertinent transport and chemical properties, when combined with one or more of therapeutic compounds and any other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers that do not deleteriously react with amino acids include, by way of example and not limitation: water, saline solution, binding agents (e.g., polyvinylpyrrolidone or hydroxypropyl methylcellulose), fillers (e.g., lactose and other sugars, gelatin, or calcium sulfate), lubricants (e.g., starch, polyethylene glycol, or sodium acetate), disintegrates (e.g., starch or sodiumstarch glycolate), and wetting agents (e.g., sodium lauryl sulfate). Pharmaceutically acceptable carriers also include aqueous pH buffered solutions or liposomes (small vesicles composed of various types of lipids, phospholipids and / or surfactants which are useful for delivery of a drug to a mammal). Further examples of pharmaceutically acceptable carriers include buffers such as phosphate, citrate, and other organic acids, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine, monosaccharides, disaccharides, and other carbohydrates including glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, saltforming counterions such as sodium, and / or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

[0129] Pharmaceutical compositions can be formulated by mixing one or more active agents with one or more physiologically acceptable carriers, diluents, and / or adjuvants, and optionally other agents that are usually incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A pharmaceutical composition can be formulated, e.g., in lyophilized formulations, aqueous solutions, dispersions, or solid preparations, such as tablets, dragees or capsules. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington’s Pharmaceutical Sciences (18th ed, Mack Publishing Company, Easton, PA (1990)), particularly Chapter 87 by Block, Lawrence, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in- oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies as described herein, provided that the active agent in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See, also, Baldrick, Regul Toxicol Pharmacol 32:210-218, 2000; Wang, IntJ Pharm 203:1-60, 2000; Charman J Pharm Sci 89:967-978, 2000; and Powell et al. PDA J Pharm Sci Technol 52:238-311, 1998), and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

[0130] Pharmaceutical compositions include, without limitation, solutions, emulsions, aqueous suspensions, and liposome-containing formulations. These compositions can begenerated from a variety of components that include, for example, preformed liquids, selfemulsifying solids and self-emulsifying semisolids. Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other; in general, emulsions are either of the water-in-oil (w / o) or oil-in-water (o / w) variety. Emulsion formulations have been widely used for oral delivery of therapeutics due to their ease of formulation and efficacy of solubilization, absorption, and bioavailability.

[0131] Compositions and formulations can contain sterile aqueous solutions, which also can contain buffers, diluents and other suitable additives (e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers). Compositions additionally can contain other adjunct components conventionally found in pharmaceutical compositions. Thus, the compositions also can include compatible, pharmaceutically active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or additional materials useful in physically formulating various dosage forms of the compositions provided herein, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. Furthermore, the composition can be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings, and aromatic substances.When added, however, such materials should not unduly interfere with the biological activities of the polypeptide components within the compositions provided herein. The formulations can be sterilized if desired.

[0132] In some embodiments, a composition containing a composition as provided herein can be in the form of a solution or powder with or without a diluent to make an injectable suspension. The composition may contain additional ingredients including, without limitation, pharmaceutically acceptable vehicles, such as saline, water, lactic acid, mannitol, or combinations thereof, for example.

[0133] Any appropriate method can be used to administer a composition as described herein to a mammal. Administration can be, for example, parenteral (e.g., by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip). Administration can be rapid (e.g., by injection) or can occur over a period of time (e.g., by slow infusion or administration of slow release formulations). In some embodiments, administration can be topical (e.g., transdermal, sublingual, ophthalmic, or intranasal), pulmonary (e.g. , by inhalation or insufflation of powders or aerosols), or oral. In addition, a composition containing a composition as described herein can be administered prior to, after, or in lieu of surgical resection of a tumor.

[0134] The antibodies, compositions, or pharmaceutical compositions provided for herein may be administered at any appropriate interval to achieve the desired effect in a subject. In some embodiments, the antibodies, compositions, or pharmaceutical compositions, are administered daily, every other day, weekly, biweekly, once every three weeks, or monthly (i.e., once every four weeks). In some embodiments, a method as provided for herein comprises administering an antibody, composition, or pharmaceutical composition to a cell or to a subject in need thereof at an interval of daily, every other day, weekly, biweekly, once every three weeks, or monthly (i.e., once every four weeks).

[0135] In some embodiments, disclosed herein is a nucleic acid molecule encoding an antibody or an amino acid sequence of any of the preceding embodiments.

[0136] In some embodiments, disclosed herein is a vector comprising the nucleic acid molecule of any of the preceding embodiments.

[0137] In some embodiments, disclosed herein is a cell comprising the nucleic acid molecule of any of the preceding embodiments, or the vector of any of the preceding embodiments.

[0138] In some embodiments, disclosed herein is a method for modulating and / or targeting Claudin 18.2 and CD3 in a biological cell, comprising contacting the cell with a composition of any of the preceding embodiments.

[0139] In some embodiments, disclosed herein is a method for modulating Claudin 18.2 activity in a biological cell comprising contacting a cell expressing Claudin 18.2 with a composition of any of the preceding embodiments.

[0140] In some embodiments, disclosed herein is a method for inhibiting the function of Claudin 18.2 in a biological cell comprising contacting a cell expressing Claudin 18.2 with a composition of any of the preceding embodiments.

[0141] In some embodiments, disclosed herein is a method for treating or preventing cancer comprising administering an effective amount of the composition of any of the preceding embodiments to a subject in need thereof.

[0142] In some embodiments, disclosed herein is a use of the composition of any of the preceding embodiments for the preparation of a medicament for the treatment of prevention of cancer.

[0143] In some embodiments, disclosed herein is a method or use of any one of the preceding embodiments, wherein the cancer is selected from one or more of basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon andrectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; glioma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; malignant rhabdoid tumor; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses; edema (e.g. that associated with brain tumors); and Meigs’ syndrome.

[0144] As a non-limiting example, the prevention of an onset, the presence, and / or the evaluation of the progression of a cancer in a subject can be assessed according to the Tumor / Nodes / Metastases (TNM) system of classification (International Union Against Cancer, 6th edition, 2002), or the Whitmore- Jewett staging system (American Urological Association). Typically, cancers are staged using a combination of physical examination, blood tests, and medical imaging. If tumor tissue is obtained via biopsy or surgery, examination of the tissue under a microscope can also provide pathologic staging. In some embodiments, the stage or grade of a cancer assists a practitioner in determining the prognosis for the cancer and in selecting the appropriate modulating therapy.

[0145] In some embodiments, the prevention of an onset, or progression, of cancer is assessed using the overall stage grouping as a non-limiting example: Stage I cancers are localized to one part of the body, typically in a small area; Stage II cancers are locally advanced and have grown into nearby tissues or lymph nodes, as are Stage III cancers. Whether a cancer is designated as Stage II or Stage III can depend on the specific type ofcancer. The specific criteria for Stages II and III can differ according to diagnosis. Stage IV cancers have often metastasized or spread to other organs or throughout the body. The onset or progression of cancer can be assessed using conventional methods available to one of skill in the art, such as a physical exam, blood tests, and imaging scans (e.g., X-rays, MRI, CT scans, ultrasound etc.).

[0146] As disclosed herein, administering, or administering a treatment / therapy, refers to a treatment / therapy from which a subject receives a beneficial effect, such as the reduction, decrease, attenuation, diminishment, stabilization, remission, suppression, inhibition or arrest of the development or progression of cancer, or a symptom thereof.

[0147] In some embodiments, the treatment / therapy that a subject receives, or the prevention in the onset of cancer results in at least one or more of the following effects: (1) the reduction or amelioration of the severity of cancer and / or a genetic disease or disorder, and / or a symptom associated therewith; (2) the reduction in the duration of a symptom associated with cancer and / or a genetic disease or disorder; (3) the prevention in the recurrence of a symptom associated with cancer and / or a genetic disease or disorder; (4) the regression of cancer and / or a genetic disease or disorder, and / or a symptom associated therewith; (5) the reduction in hospitalization of a subject; (6) the reduction in hospitalization length; (7) the increase in the survival of a subject; (8) the inhibition of the progression of cancer and / or a genetic disease or disorder and / or a symptom associated therewith; (9) the enhancement or improvement the therapeutic effect of another therapy; (10) a reduction or elimination in the cancer cell population, and / or a cell population associated with a genetic disease or disorder; (11) a reduction in the growth of a tumor or neoplasm; (12) a decrease in tumor size; (13) a reduction in the formation of a tumor; (14) eradication, removal, or control of primary, regional and / or metastatic cancer; (15) a decrease in the number or size of metastases; (16) a reduction in mortality; (17) an increase in cancer-free survival rate of a subject; (18) an increase in relapse-free survival; (19) an increase in the number of subjects in remission; (20) a decrease in hospitalization rate; (21) the size of the tumor is maintained and does not increase in size or increases the size of the tumor by less 5% or 10% after administration of a therapy as measured by conventional methods available to one of skill in the art, e.g., X-rays, MRI, CAT scan, ultrasound etc.; (22) the prevention of the development or onset of cancer and / or a genetic disease or disorder, and / or a symptom associated therewith; (23) an increase in the length of remission for a subject; (24) the reduction in the number of symptoms associated with cancer and / or a genetic disease or disorder; (25) an increase in symptom-free survival of a cancer subject and / or a subject associated with agenetic disease or disorder; and / or (26) limitation of or reduction in metastasis. In some embodiments, the treatment / therapy that a subject receives does not cure cancer, but prevents the progression or worsening of the disease. In certain embodiments, the treatment / therapy that a subject receives does not prevent the onset / development of cancer, but may prevent the onset of cancer symptoms.

[0148] In some embodiments, the subject that is treated does not develop cytokine release syndrome (CRS), or does not develop significant CRS -associated clinical symptoms or toxicity. These symptoms include, but are not limited to fever, chills, fatigue, weakness, loss of appetite, nausea, vomiting, diarrhea, headache, joint or muscle aches, skin rash, low blood pressure, increased heart rate, irregular heartbeat, tachycardia, decreased heart function, swelling, buildup of fluids (edema), confusion, dizziness, seizures, hallucinations, decreased coordination, problems talking or swallowing, shaking, problems controlling movements, cough, shortness of breath, tachypnoea, decreased lung function, reduced oxygen levels, decreased kidney or liver function, increased cytokine levels in the blood, change in electrolytes, change in blood clotting. In some embodiments, there is no increase or no significant increase in the blood levels of interleukin-6 (IL-6), interleukin- 10 (IL-10), interferon (IFN)-γ, monocyte chemoattractant protein 1 (MCP-1) granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF), IL-1, IL-2, IL-2-receptor- α, or IL-8 after administration of an antibody as provided for herein.

[0149] In some embodiments, “preventing” an onset or progression of cancer in a subject in need thereof, is inhibiting or blocking the cancer or disorder. In some embodiments, the methods disclosed herein prevent, or inhibit, the cancer or disorder at any amount or level. In some embodiments, the methods disclosed herein prevent or inhibit the cancer or genetic disease or disorder by at least or about a 10% inhibition (e.g., at least or about a 20% inhibition, at least or about a 30% inhibition, at least or about a 40% inhibition, at least or about a 50% inhibition, at least or about a 60% inhibition, at least or about a 70% inhibition, at least or about a 80% inhibition, at least or about a 90% inhibition, at least or about a 95% inhibition, at least or about a 98% inhibition, or at least or about a 100% inhibition).

[0150] In some embodiments, disclosed herein is an isolated antibody comprising one or more of the sequences disclosed herein.Delivery and. Vectors

[0151] Disclosed herein, in some embodiments, are nucleic acid sequences encoding an antibody described herein or components thereof.

[0152] In some embodiments, the nucleic acid encoding the antibody described herein or components thereof is a DNA, for example a linear DNA, a plasmid DNA, or a minicircle DNA. In some embodiments, the nucleic acid encoding the antibody described herein or components thereof is an RNA, for example a mRNA.

[0153] In some embodiments, the nucleic acid encoding the antibody described herein or components thereof is delivered by a nucleic acid-based vector. In some embodiments, the nucleic acid-based vector is a plasmid (e.g., circular DNA molecules that can autonomously replicate inside a cell), cosmid (e.g., pWE or sCos vectors), artificial chromosome, human artificial chromosome (HAC), yeast artificial chromosomes (YAC), bacterial artificial chromosome (BAC), Pl-derived artificial chromosomes (PAC), phagemid, phage derivative, bacmid, or virus. In some embodiments, the nucleic acid-based vector is selected from the list consisting of: pSF-CMV-NEO-NH2-PPT-3XFLAG, pSF-CMV-NEO-COOH-3XFLAG, pSF-CMV-PURO-NH2-GST-TEV, pSF-OXB20-COOH-TEV-FLAG(R)-6His, pCEP4 pDEST27, pSF-CMV-Ub-KrYFP, pSF-CMV-FMDV-daGFP, pEFla-mCherry-Nl vector, pEFla-tdTomato vector, pSF-CMV-FMDV-Hygro, pSF-CMV-PGK-Puro, pMCP-tag(m), pSF-CMV-PURO-NH2-CMYC, pSF-OXB20-BetaGal,pSF-OXB20-Fluc, pSF-OXB20, pSF- Tac, pRI 101-AN DNA, pCambia2301, pTYB21, pKLAC2, pAc5.1 / V5-His A, and pDEST8.

[0154] In some embodiments, the nucleic acid-based vector comprises a promoter. In some embodiments, the promoter is selected from the group consisting of a mini promoter, an inducible promoter, a constitutive promoter, and derivatives thereof. In some embodiments, the promoter is selected from the group consisting of CMV, CBA, EFla, CAG, PGK, TRE, U6, UAS, T7, Sp6, lac, araBad, trp, Ptac, p5, pl9, p40, Synapsin, CaMKII, GRK1, and derivatives thereof. In some embodiments the promoter is a U6 promoter. In some embodiments, the promoter is a CAG promoter.

[0155] In some embodiments, the nucleic acid-based vector is a virus. In some embodiments, the virus is an alphavirus, a parvovirus, an adenovirus, an AAV, a baculovirus, a Dengue virus, a lentivirus, a herpesvirus, a poxvirus, an anellovirus, a bocavirus, a vaccinia virus, or a retrovirus. In some embodiments, the virus is an alphavirus. In some embodiments, the virus is a parvovirus. In some embodiments, the virus is an adenovirus. In some embodiments, the virus is an AAV. In some embodiments, the virus is a baculovirus. In some embodiments, the virus is a Dengue virus. In some embodiments, the virus is a lentivirus. In some embodiments, the virus is a herpesvirus. In some embodiments, the virus is a poxvirus. In some embodiments, the virus is an anellovirus. In some embodiments, the virus is abocavirus. In some embodiments, the virus is a vaccinia virus. In some embodiments, the virus is or a retrovirus.

[0156] In some embodiments, the AAV is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV-rh8, AAV-rhlO, AAV-rh20, AAV-rh39, AAV-rh74, AAV-rhM4-l, AAV-hu37, AAV-Anc80, AAV-Anc80L65, AAV-7m8, AAV-PHP-B, AAV-PHP-EB, AAV-2.5, AAV-21YF, AAV-3B, AAV-LK03, AAV-HSC1, AAV-HSC2, AAV-HSC3, AAV-HSC4, AAV-HSC5, AAV-HSC6, AAV-HSC7, AAV-HSC8, AAV-HSC9, AAV-HSC10, AAV-HSC11 , AAV-HSC12, AAV-HSC13, AAV-HSC14, AAV-HSC15, AAV-TT, AAV-DJ / 8, AAV-Myo, AAV-NP40, AAV-NP59, AAV-NP22, AAV-NP66, AAV-HSC16, or a derivative thereof. In some embodiments, the herpesvirus is HSV type 1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7, or HHV-8.

[0157] In some embodiments, the nucleic acid encoding the antibody described herein or components thereof is delivered by a non-nucleic acid-based delivery system (e.g., a non- viral delivery system). In some embodiments, the non-viral delivery system is a liposome. In some embodiments, the nucleic acid is associated with a lipid. The nucleic acid associated with a lipid, in some embodiments, is encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the nucleic acid, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. In some embodiments, the nucleic acid is comprised in a lipid nanoparticle (LNP).

[0158] In some embodiments, the antibody described herein or components thereof is introduced into the cell in any suitable way, either stably or transiently. In some embodiments, the antibody described herein or components thereof is transfected into the cell. In some embodiments, the cell is transduced or transfected with a nucleic acid construct that encodes the antibody described herein or components thereof. For example, a cell is transduced (e.g., with a virus encoding the antibody described herein or components thereof), or transfected (e.g., with a plasmid encoding the antibody described herein or components thereof) with a nucleic acid that encodes the antibody described herein or components thereof, or the translated the antibody described herein or components thereof. In some embodiments, the transduction is a stable or transient transduction. In some embodiments, a plasmid expressing the antibody described herein or components thereof is introduced intocells through electroporation, transient (e.g., lipofection) and stable genome integration (e.g., piggybac) and viral transduction (for example lentivirus or AAV) or other methods known to those of skill in the art. In some embodiments, the gene editing system is introduced into the cell as one or more polypeptides. In some embodiments, delivery is achieved through the use of RNP complexes. Delivery methods to cells for polypeptides and / or RNPs are known in the art, for example by electroporation or by cell squeezing.

[0159] Exemplary methods of delivery of nucleic acids include lipofection, nucleofection, electroporation, stable genome integration (e.g., piggybac), microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386; 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™, Lipofectin™ and SF Cell Line 4D-Nucleofector X Kit™ (Lonza)). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of WO 91 / 17424 and WO 91 / 16024. In some embodiments, the delivery is to cells (e.g., in vitro or ex vivo administration) or target tissues (e.g., in vivo administration). In some embodiments, the nucleic acid is comprised in a liposome or a nanoparticle that specifically targets a host cell.

[0160] Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US 2003 / 0087817.

[0161] In some embodiments, a nucleic acid molecule encoding an antibody or a component thereof described herein includes one or more of the DNA sequences provided in TABLE B. In some embodiments, the nucleic acid molecule comprises a sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity to any one of SEQ ID NOs: 5210-5236.

[0162] In some embodiments, a nucleic acid molecule encoding an antibody or a component thereof described herein includes one or more of the RNA sequences provided in TABLE C. In some embodiments, the nucleic acid molecule comprises a sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity to any one of SEQ ID NOs: 5237-5263.TABLE B: DNA Sequences Encoding Antibody or a Component Thereof DescribedHereinTABLE C: RNA Sequences Encoding Antibody or a Component Thereof DescribedHereinLipid nanoparticles

[0163] Disclosed herein, in certain embodiments, are lipid nanoparticles comprising an antibody or components thereof of the disclosure for delivery of the antibody into a cell.

[0164] In some embodiments, the lipid nanoparticle comprises the antibody or a nucleic acid encoding the antibody or components thereof.

[0165] In some embodiments, the lipid nanoparticle is tethered to the antibody or a nucleic acid encoding the antibody or components thereof.

[0166] Lipid nanoparticles as described herein can be 4-component lipid nanoparticles. Such nanoparticles can be configured for delivery of RNA or other nucleic acids (e.g., synthetic RNA, mRNA, or in vitro-synthesized mRNA) and can be generally formulated as described in WO2012135805A2. Such nanoparticles can generally comprise: (a) a cationic lipid, (b) a neutral lipid (e.g., DSPC or DOPE), (c) a sterol (e.g., cholesterol or a cholesterol analog), or (d) a PEG-modified lipid (e.g., PEG-DMG).

[0167] The cationic lipid referred to herein as “C 12-200” is disclosed by Love et al., Proc Natl Acad Sci USA. 2010 107:1864-1869 and Liu and Huang, Molecular Therapy. 2010 669- 670. Cationic lipid formulations can include particles comprising either 3 or 4 or more components in addition to polynucleotide, primary construct, or RNA (e.g., mRNA). As an example, formulations with certain cationic lipids, include, but are not limited to, 98N12-5 and may contain 42% lipidoid, 48% cholesterol and 10% PEG (C14 or greater alkyl chain length). As another example, formulations with certain lipidoids include, but are not limited to, C12-200 and may contain 50% cationic lipid, 10% disteroylphosphatidyl choline, 38.5% cholesterol, and 1.5% PEG-DMG.

[0168] In some embodiments, the cationic lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol, and a non-cationic lipid. In some embodiments, the cationic lipid nanoparticle has a molar ratio of about 20-60% cationic lipid: about 5-25% non-cationic lipid: about 25-55% sterol; and about 0.5-15% PEG-modified lipid. In some embodiments, the cationic lipid nanoparticle comprises a molar ratio of about 50% cationic lipid, about 1.5% PEG-modified lipid, about 38.5% cholesterol, and about 10% non-cationic lipid. In some embodiments, the cationic lipid nanoparticle comprises a molar ratio of about 55% cationic lipid, about 2.5% PEG-modified lipid, about 32.5% cholesterol, and about 10% noncationic lipid. In some embodiments, the cationic lipid is an ionizable cationic lipid, the noncationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, the cationic lipid nanoparticle has a molar ratio of 50:38.5: 10: 1 .5 of cationic lipid: cholesterol: PEG2000-DMG:DSPC or DMG:DOPE. In some embodiments, lipid nanoparticles as described herein can comprise cholesterol, 1,2-dioleoyl-sn-glycero-3 -phosphoethanolamine (DOPE), 1 , 1 ‘-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2- hydroxydodecyl)amino)ethyl)piperazin- 1 -yl)ethyl)azanediyl)bis(dodecan-2-ol) (C 12-200), and DMG-PEG-2000 at molar ratios of 47.5:16:35:1.5.

[0169] In some embodiments, the lipid nanoparticle comprises 1,1'-[[2-[4-[2-[[2-[bis(2- hydroxydodecyl)amino]ethyl](2-hydroxydodecyl)amino]ethyl]-l- piperazinyl]ethyl]imino]bis-2-dodecanol (C12-200), a sterol (e.g., cholesterol, campesterol,or β-sitosterol), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and 1,2- dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (C14:0 PEG2000 PE). In some embodiments, the lipid nanoparticle comprises 1,1'-[[2-[4-[2-[[2-[bis(2-hydroxydodecyl)amino]ethyl](2- hydroxydodecyl)amino]ethyl]-l-piperazinyl]ethyl]imino]bis-2-dodecanol (C12-200), sterol (e.g., cholesterol, campesterol, or β-sitosterol), 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE), 1 ,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy(polyethylene glycol)-2000] (ammonium salt) (C14:0 PEG2000 PE), and 1 ,2- distearoyl-sn-glycero-3-phosphoethanolamine-N-[tris-GalNAc-Y-aminobutyric acid- (polyethylene glycol)-2000.

[0170] In some embodiments, the lipid nanoparticle comprises (9Z,12Z)-3-((4,4- Bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9, 12-dienoate (LP01), a sterol (e.g., cholesterol, campesterol, or β-sitosterol), 1,2- dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1 ,2-dioctadecanoyl-sn-glycero-3- phosphocholine (DS PC), and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol- 2000 (DMG-PEG 2000). In some embodiments, the lipid nanoparticle comprises (9Z,12Z)-3- ((4,4-Bis(octyloxy)butanoyl)oxy)-2-((((3- (diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9, 12-dienoate (LP01), a sterol (e.g., cholesterol, campesterol, or β-sitosterol), 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE), 1,2-dioctadecanoyl-sn-glycero-3 -phosphocholine (DSPC), 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG 2000), and 1,2- distearoyl-sn-glycero-3-phosphoethanolamine-N-[tris-GalNAc-Y-aminobutyric acid- (polyethylene glycol)-2000. In some embodiments, the lipid nanoparticle comprises (9Z,12Z)-3-((4,4-Bis(octyloxy)butanoyl)oxy)-2-((((3- (diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9, 12-dienoate (LP01 ) , cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioctadecanoyl-sn- glycero-3-phosphocholine (DSPC), and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG 2000). In some embodiments, the lipid nanoparticle comprises (9Z, 12Z)-3-((4,4-Bis(octyloxy)butanoyl)oxy)-2-((((3- (diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9, 12-dienoate (LP01 ) , cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioctadecanoyl-sn- glycero-3-phosphocholine (DSPC), 1 ,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG 2000), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [tris-GalNAc-Y-aminobutyric acid-(polyethylene glycol)-2000.

[0171] In some embodiments, the lipid nanoparticles comprises (9Z,12Z)-3-((4,4- Bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate (LP-01), cholesterol, 1,2-dioctadecanoyl-sn-glycero-3- phosphocholine (DSPC) and 1 ,2-dimyristoyl-rac-glycero-3 -methoxypolyethylene glycol- 2000 (DMG-PEG 2000).

[0172] In some embodiments, the lipid nanoparticles comprises one of the phospholipids selected from 1,2-dioleoyl-sn-glycero-3 -phosphoethanolamine (DOPE), 1,2-dilinolenoyl-sn- glycero-3-phosphoethanolamine (18:3 PE), 1,2-didocosahexaenoyl-sn-glycero-3- phosphoethanolamine (22:6 PE), and 1,2-dioleoyl-sn-glycero-3 -phosphocholine (DOPC).

[0173] In some embodiments, the lipid nanoparticle comprises of different lipids comprising (9Z,12Z)-3-((4,4-Bis(octyloxy)butanoyl)oxy)-2-((((3- (diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9, 12-dienoate (LP-01 ), cholesterol, 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine (DSPC), 1 ,2-dimyristoyl-rac- glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG 2000), 1 ,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-|tris-GalNAc-Y-aminobutyric acid- (polyethylene glycol)-2000, Tris-β-GalNAc-GABA-PEG2000-DSPE (GalNAc).

[0174] As used herein, the word “include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, compositions, devices, and methods of this technology. Similarly, the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features. Although the open-ended term “comprising,” as a synonym of terms such as including, containing, or having, is used herein to describe and claim the disclosure, the present technology, or embodiments thereof, may alternatively be described using more limiting terms such as “consisting of” or “consisting essentially of” the recited ingredients.

[0175] Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials, similar or equivalent to those described herein, can be used in the practice or testing of the present disclosure, the preferred methods and materials are described herein. All publications, patents, and patent publications cited are incorporated by reference herein in their entirety for all purposes.

[0176] This disclosure is further illustrated by the following non-limiting examples.EXAMPLES

[0177] The subject matter is now described with reference to the following examples. These examples are provided for the purpose of illustration only and the claims should in no way be construed as being limited to these examples, but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein. Those of skill in the art will readily recognize a variety of non-crilical parameters that could be changed or modified to yield essentially similar results.Example 1: Overview and Development of Antibodies Specific for Claudin 18.2 and CD3

[0178] The experiments in this example demonstrated certain features of antibodies specific for Claudin 18.2 and CD3. In this example, antibodies specific for Claudin 18.2 and CD3 were engineered and characterized. This example provided tandem scFv antibodies, scFv-Fab IgG antibodies, IgG-(scFv)2antibodies, and IgG-(scFv) antibodies specific for Claudin 18.2 and CD3 (FIG. 1).

[0179] To develop bispecific antibodies to Claudin 18.2 and CD3, a panel of constructs were generated using the following antibody formats: tandem scFv, scFv-Fab IgG, IgG-scFv, IgG-(scFv)2, and IgG-(scFv). Potential Claudin 18.2-specific arms included those from 4409- B03, 4401 -E10, and 4405-H06 antibodies, and specific CD3 arms included those from hsOKT3 and pasotuxizumab antibodies, as well as a nanobody. Antibodies tested are provided in TABLEs 6-9, as follows:TABLE 6: Tandem scFvsTABLE 7: scFv-Fab IgGTABLE 8: IgG-(scFv)2TABLE 9: IgG-(scFv)Example 2: Functional and Developability Characterization of IM-16-44-09-B03-1CD3

[0180] FIG. 2 shows that IM-16-44-09-B03-1CD3 bound to both human Claudin 18.2(“CLDN 18.2”) and human CD3. Flow cytometry experiments were performed to test the ability of the IM-16-44-09-B03-1CD3 antibody to bind HEK293F cells expressing human CLDN 18.2, human CD3, or human P2X3. HEK293F cells were transfected by lipofectamine with target and control plasmids. At 18-24 hours post-transfection, cells were stained with bispecific and control MAbs followed by APC -labelled goat anti-human antibody.Fluorescence was detected using an Intellicyt high-throughput flow cytometer (iQue; Intellicyt, Albuquerque, NM). As shown in FIG. 2, IM-16-44-09-B03-1CD3 selectively bound to both human CLDN 18.2 and human CD3, and not P2X3.

[0181] FIG. 3 shows cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) were co-cultured with human Claudin 18.1 (“CLDN 18.1”) or CLDN 18.2-expressing HEK293F cells (2500 cells / well) also expressing Firefly Luciferase (ffLuciferase) in the presence of IMC-16-C2 (control antibody) or IM- 16-44-09-B03-1CD3 antibodies. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated. As shown in FIG. 3, killing was only potently induced against CLDN 18.2- expressing gastric cancer cells by the IM-16-44-09-B03-1CD3 antibody. No killing activity was observed using the control antibody or against cells expressing CLDN 18.1.

[0182] FIGs. 4A, 4B, 4C, 4D, and 4E show cytokines produced by human peripheral blood mononuclear cells (PBMC) cultured with IMC-16-C2 or IM-16-44-09-B03-1CD3 antibodies and human CLDN 18.1 - or 18.2-expressing cells (HEK293F). FIG. 4A shows the levels of IL-2, FIG. 4B shows the levels of IL-6, FIG. 4C shows the levels of IL- 10, FIG. 4D shows the levels of IFN-γ (gamma), and FIG. 4E shows the levels of TNF-α (alpha) produced by human PBMCs in the presence of human CLDN 18.1- or 18.2-expressing cells and IMC-16- C2 or IM-16-44-09-B03-1CD3 antibodies. These experiments showed that IL-2, IL-6, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMC by the IM-16-44-09-B03-1CD3 antibody in the presence of CLDN 18.2-expressing cells.

[0183] FIGs. 5A and 5B show size exclusion chromatography (SEC) and differential scanning fhiorimetry (DSF) experimental results for the IM-16-44-09-B03-1CD3, IM-16-44- 09-B03-2CD3, and IM-16-44-09-B03-3CD3 antibodies. SEC was performed using an AKTA FPLC with a Superdex 200 increase 3.2 / 300 SEC column. Samples (0.1 ml) were run in PBS at a concentration of 0.5 to 1 mg / ml. DSF was performed by mixing 20 μL antibody (0.1 mg / ml) with 10 μL of Sypro Orange (BioRad). Fluorescence was monitored as a function of temperature (45 °C to 95 °C) using a real-time PCR machine. These experiments were utilized for developability assessment (including, without limitation, large-scale yield). TABLE 10 details developability parameters for each of the aforementioned antibodies.TABLE 10: Developability parameters based on SEC and DSF experiments with IM- 16-44- 09-B03-1CD3, IM-16-44-09-B03-2CD3, and IM-16-44-09-B03-3CD3 antibodiesExample 3: Functional and Developability Characterization of I M-21-44-01 -E10-3 CD3

[0184] FIG. 6 shows that 1M-21-44-01-E10-3CD3 bound to both human CLDN 18.2 and human CD3. Flow cytometry experiments were performed to test the ability of the IM-21-44- 01-E10-3CD3 antibody to bind HEK293F cells expressing human CLDN 18.2, human CD3, or human P2X3. HEK293F cells were transfected by lipofectamine with target and control plasmids. At 18-24 hours post-transfection, cells were stained with bispecific and control MAbs followed by APC-labelled goat anti-human antibody. Fluorescence was detected using an Intellicyt high-throughput flow cytometer (iQue; Intellicyt, Albuquerque, NM). As shown in FIG. 6, IM-21 -44-01-E10-3CD3 selectively bound to both human CLDN 18.2 and human CD3, and not P2X3.

[0185] FIG. 7 shows cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) were co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IMC-16-C2 (control antibody) or IM-21 -44-01-E10-3CD3 antibodies. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated. As shown in FIG. 7, killing was only potently induced against CLDN 18.2-expressing cells by the IM-21-44-01 -E10-3CD3 antibody. No killing activity was observed using the control antibody or against cells expressing CLDN 18.1.

[0186] FIGs. 8A, 8B, 8C, 8D, and 8E show cytokines produced by human PBMC cultured with IMC-16-C2 or IM-16-44-09-B03-1CD3 antibodies and human CLDN 18.1- or 18.2- expressing cells. FIG. 8A shows the levels of IL-2, FIG. 8B shows the levels of IL-6, FIG.8C shows the levels of IL-10, FIG. 8D shows the levels of IFN-γ (gamma), and FIG. 8E shows the levels of TNF-α (alpha) produced by human PBMCs in the presence of humanCLDN 18.1- or 18.2-expressing cells and the IMC-16-C2 or IM-21-44-01-E10-3CD3 antibodies. These experiments showed that IL-2, IL-6, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMC by the IM-21-44-01-E10-3CD3 18.2 antibody in the presence of CLDN 18.2-expressing cells.

[0187] FIGs. 9 A and 9B show SEC and DSF experimental results for IM-21-44-01 -E10- 1CD3, IM-21 -44-01-E10-2CD3, and IM-21-44-01-E10-3CD3 antibodies. SEC was performed using an AKTA FPLC with a Superdex 200 increase 3.2 / 300 SEC column.Samples (0.1 ml) were run in PBS at a concentration of 0.5 to 1 mg / ml. DSF was performed by mixing 20 μL antibody (0.1 mg / ml) with 10 μL of Sypro Orange (BioRad). Fluorescence was monitored as a function of temperature (45 °C to 95 °C) using a real-time PCR machine. These experiments were utilized for developability assessment (including, without limitation, large-scale yield). TABLE 11 details developability parameters for each of the aforementioned antibodies.TABLE 11: Developability parameters based on SEC and DSF experiments with IM-21 -44- 01-E10-1CD3, IM-21 -44-01-E10-2CD3, and IM-21 -44-01-E10-3CD3 antibodiesExample 4: Functional and. Developability Characterization of IM-21-44-09-B03-3CD3

[0188] FIG. 10 shows that IM-21-44-09-B03-3CD3 bound to both human CLDN 18.2 and human CD3. Flow cytometry experiments were performed to test the ability of the IM-21-44- 01-E10-3CD3 antibody to bind HEK-293F cells expressing human CLDN 18.2, human CD3, or human P2X3. HEK-293F cells were transfected by lipofectamine with target and control plasmids. At 18-24 hours post transfection, cells were stained with bispecific and control MAbs followed by APC-labelled goat anti-human antibody. Fluorescence was detected using an Intellicyt high-throughput flow cytometer (iQue; Intellicyt, Albuquerque, NM). As shown in FIG. 10, IM-21-44-09-B03-3CD3 selectively bound to both human CLDN 18.2 and human CD3, and not P2X3.

[0189] FIG. 11 shows cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) were co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IMC-16-C2 (control antibody) or IM-21-44-09-B03-3CD3 antibodies. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated. As shown in FIG. 11, killing was only potently induced against CLDN 18.2-expressing cells by the IM-21-44-09-B03-3CD3 antibody. No killing activity was observed using the control antibody or against cells expressing CLDN 18.1.

[0190] FIGs. 12A, 12B, 12C, 12D, and 12E show cytokines produced by human PBMC cultured with the IMC-16-C2 or IM-21-44-09-B03-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 12A shows the levels of IL-2, FIG. 12B shows the levels of IL-6, FIG. 12C shows the levels of IL-10, FIG. 12D shows the levels of IFN-γ (gamma), and FIG. 12E shows the levels of TNF-α (alpha) produced by human PBMCs in the presence of human CLDN 18.1- or 18.2-expressing cells and IMC-16-C2 or IM-21-44-09-B03-3CD3 antibodies. These experiments showed that IL-2, IL-6, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMC by the IM-21-44-09-B03-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0191] FIGs. 13A and 13B show SEC and DSF experimental results for IM-21 -44-09-B03- 1CD3, IM-21-44-09-B03-2CD3, and IM-21 -44-09-B03-3CD3 antibodies. SEC was performed using an AKTA FPLC with a Superdex 200 increase 3.2 / 300 SEC column.Samples (0.1 ml) were run in PBS at a concentration of 0.5 to 1 mg / ml. DSF was performed by mixing 20 μl antibody (0.1 mg / ml) with 10 μl of Sypro Orange (BioRad). Fluorescence was monitored as a function of temperature (45 °C to 95 °C) using a real-time PCR machine.These experiments were utilized for developability assessment (including, without limitation, large-scale yield). TABLE 12 details developability parameters for each of the aforementioned antibodies.TABLE 12: Developability parameters based on SEC and DSF experiments with IM-21 -44- 09-B03-1CD3, IM-21 -44-09-B03-2CD3, and IM-21 -44-09-B03-3CD3 antibodiesExample 5: Functional Characterization of IM-2-44-05-H06-1CD3

[0192] FIG. 14 shows that IM-2-44-05-H06-1CD3 bound to both human CLDN 18.2 and human CD3. Flow cytometry experiments were performed to test the ability of the IM-2-44- 05-H06-1CD3 antibody to bind HEK293F cells expressing human CLDN 18.2, human CD3, or human P2X3. HEK293F cells were transfected by lipofectamine with target and control plasmids. At 18-24 hours post transfection, cells were stained with bispecific and control MAbs followed by APC-labelled goat anti-human antibody. Fluorescence was detected using an Intellicyt high-throughput flow cytometer (iQue; Intellicyt, Albuquerque, NM). As shown in FIG. 14, IM-2-44-05-H06-1CD3 selectively bound to both human CLDN 18.2 and human CD3, and not P2X3.

[0193] FIG. 15 shows cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) were co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IMC-16-C2 (control antibody) or IM-2-44-05-H06-1CD3 antibodies. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated. As shown in FIG. 15, killing was only potently induced against CLDN 18.2-expressing cells by the IM-2-44-05 -H06-1CD3 antibody. No killing activity was observed using the control antibody or against cells expressing CLDN 18.1.

[0194] FIGs. 16A, 16B, 16C, 16D, and 16E show cytokines produced by human PBMC cultured with the IMC-16-C2 or IM-2-44-05 -H06-1CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 16A shows the levels of IL-2, FIG. 16B shows the levels of IL-6, FIG. 16C shows the levels of IL- 10, FIG. 16D shows the levels of IFN-γ (gamma), and FIG. 16E shows the levels of TNF-α (alpha) produced by human PBMCs in the presence of human CLDN 18.1- or 18.2-expressing cells and IMC-16-C2 or IM-2-44-05-H06-1CD3 antibodies. These experiments showed, inter alia, that IL-2, IL-6, IL-10, IFN-γ, and TNF-α were selectively induced in human PBMC by the IM-2-44-05 -H06-1CD3 in the presence of human CLDN 18.2-expressing cells.Example 6: Functional Characterization of IM-2-44-09-B03-1CD3

[0195] FIG. 17 shows that IM-2-44-09-B03-1CD3 bound to both human CLDN 18.2 and human CD3. Flow cytometry experiments were performed to test the ability of the IM-2-44- 09-B03-1CD3 antibody to bind HEK-293F cells expressing human CLDN 18.2, human CD3, or human P2X3. HEK293F cells were transfected by lipofectamine with target and control plasmids. At 18-24 hours post transfection, cells were stained with bispecific and control MAbs followed by APC-labelled goat anti-human antibody. Fluorescence was detected using an Intellicyt high-throughput flow cytometer (iQue; Intellicyt, Albuquerque, NM).-As shown in FIG. 17, IM-2-44-09-B03-1CD3 selectively bound to both human CLDN 18.2 and human CD3, and not P2X3.

[0196] FIG. 18 shows cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) were co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IMC-16-C2 (control antibody) or IM-2-44-09-B03-1CD3 antibodies. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit(Promega) and percent cell killing was calculated. As shown in FIG. 18, killing was only potently induced against CLDN 18.2 expressing cells by the IM-2-44-09-B03-1CD3 antibody. No killing activity was observed using the control antibody or against cells expressing CLDN 18.2.

[0197] FIGs. 19A, 19B, 19C, 19D, and 19E show cytokines produced by human PBMC cultured with the IMC-16-C2 or IM-2-44-09-B03-1CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 19A shows the levels of IL-2, FIG. 19B shows the levels of IL-6, FIG. 19C shows the levels of IL-10, FIG. 19D shows the levels of IFN-γ (gamma), and FIG. 19E shows the levels of TNF-α (alpha) produced by human PBMCs in the presence of human CLDN 18.1- or 18.2-expressing cells and IMC-16-C2 or IM-2-44-09-B03-1CD3 antibodies. These experiments showed that IL-2 , IL-6, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMC by the IM-2-44-09-B03-1CD3 antibody in the presence of human CLDN 18.1 or 18.2-expressing cells .Example 7: Cytotoxicity Characterization ofIMC-16-C2 (Control Antibody)

[0198] FIG. 20 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. FIG. 20 shows cytotoxicity data of human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IMC-16-C2 control antibodies. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated. These experiments showed that killing was not induced against human CLDN 18.1- or 18.2-expressing cells by the IMC-16-C2 control antibody.Example 8: Functional Characterization of IM-42-44-09-B03-1CD3

[0199] FIG. 21 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well)in the presence of IM-42-44-09-B03-1CD3 antibodies induced killing against human CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0200] FIGs. 22A, 22B, 22C, 22D, and 22E show cytokines produced by human PBMC cultured with IM-42-44-09-B03-1CD3 antibodies and human CLDN 18.1- or 18.2-expressingcells. FIG. 22A shows the levels of IL-2, FIG. 22B shows the levels of IL-6, FIG. 22C shows the levels of IL-10, FIG. 22D shows the levels of IFN-γ (gamma), and FIG. 22E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-09-B03-1CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that TNF-α was selectively induced in human PBMCs by the IM-42-44-09-B03-1CD3 antibody in the presence of human CLDN 18.2- expressing cells.

[0201] FIGs. 23A, 23B, 23C, 23D, and 23E shows cytokines produced by human PBMC cultured with IM-42-44-09-B03-1CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 23A shows the levels of IL-2, FIG. 23B shows the levels of IL-6, FIG. 23C shows the levels of IL-10, FIG. 23D shows the levels of IFN-γ (gamma), and FIG. 23E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-09-B03-1CD3 antibodies at the 48 hour (48hr) timepoint. These experiments showed that IFN-γ was selectively induced in human PBMCs by the IM-42-44-09-B03-1CD3 antibody in the presence of human CLDN 18.2- expressing cells.Example 9: Functional Characterization of IM-42-44-09-B03-3CD3

[0202] FIG. 24 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence IM-42-44-09-B03-3CD3 antibodies induced killing against human CLDN 18.2 expressing cells but not human CLDN 18.1 expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0203] FIGs. 25A, 25B, 25C, 25D, and 25E shows cytokines produced by human PBMC cultured with IM-42-44-09-B03-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 25A shows the levels of IL-2, FIG. 25B shows the levels of IL-6, FIG. 25C shows the levels of IL-10, FIG. 25D shows the levels of IFN-γ (gamma), and FIG. 25E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-09-B03-3CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by the IM-42-44-09-B03-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0204] FIGs. 26A, 26B, 26C, 26D, and 26E shows cytokines produced by human PBMC cultured with IM-42-44-09-B03-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 26A shows the levels of IL-2, FIG. 26B shows the levels of IL-6, FIG. 26C shows the levels of IL-10, FIG. 26D shows the levels of IFN-γ (gamma), and FIG. 26E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-09-B03-3CD3 antibodies al the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by the IM-42-44-09-B03-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 10: Functional Characterization of IM-42-44-01-E10-1CD3

[0205] FIG. 27 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IM-42-44-01-E10-1CD3 induced killing against CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0206] FIGs. 28A, 28B, 28C, 28D, and 28E shows cytokines produced by human PBMC cultured with IM-42-44-01-E10-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 28A shows the levels of IL-2, FIG. 28B shows the levels of IL-6, FIG. 28C shows the levels of IL-10, FIG. 28D shows the levels of IFN-γ (gamma), and FIG. 28E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM -42-44-01 -E10-3CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by the IM-42-44-01-E10-1CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0207] FIGs. 29A, 29B, 29C, 29D, and 29E shows cytokines produced by human PBMC cultured with IM-42-44-01-E10-1CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 29A shows the levels of IL-2, FIG. 29B shows the levels of IL-6, FIG. 29C shows the levels of IL-10, FIG. 29D shows the levels of IFN-γ (gamma), and FIG. 29E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-01-E10-1CD3 antibodies at the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α wereselectively induced in human PBMCs by the IM-42-44-01-E10-1CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 11: Functional Characterization of IM-42-44-01-E10-3CD3

[0208] FIG. 30 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IM-42-44-01 -E10-3CD3 antibodies induced killing against human CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0209] FIGs. 31A, 31B, 31C, 31D, and 31E shows cytokines produced by human PBMC cultured with IM-42-44-01-E10-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 31A shows the levels of IL-2, FIG. 31B shows the levels of IL-6, FIG. 31C shows the levels of IL-10, FIG. 31D shows the levels of IFN-γ (gamma), and FIG. 31E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM -42-44-01 -E10-3CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by the IM-42-44-01 -E10-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0210] FIGs. 32A, 32B, 32C, 32D, and 32E shows cytokines produced by human PBMC cultured with IM-42-44-01-E10-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 32A shows the levels of IL-2, FIG. 32B shows the levels of IL-6, FIG. 32C shows the levels of IL-10, FIG. 32D shows the levels of IFN-γ (gamma), and FIG. 32E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM -42-44-01 -E10-3CD3 antibodies at the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by the IM-42-44-01 -E10-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 12: Functional Characterization of IM-42-44-05-H06-1CD3

[0211] FIG. 33 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presenceof IM-42-44-05-H06-1CD3 antibodies induced killing against human CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0212] FIGs. 34A, 34B, 34C, 34D, and 34E shows cytokines produced by human PBMC cultured with IM-42-44-05-H06-1CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 34A shows the levels of IL-2, FIG. 34B shows the levels of IL-6, FIG. 34C shows the levels of IL-10, FIG. 34D shows the levels of IFN-γ (gamma), and FIG. 34E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-05-H06-1CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by IM-42-44-05 -H06-1CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0213] FIGs. 35A, 35B, 35C, 35D, and 35E shows cytokines produced by human PBMC cultured with IM-42-44-05-H06-1CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 35A shows the levels of IL-2, FIG. 35B shows the levels of IL-6, FIG. 35C shows the levels of IL-10, FIG. 35D shows the levels of IFN-γ (gamma), and FIG. 35E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-05-H06-1CD3 antibodies at the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by the IM-42-44-05 -H06-1CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 13: Functional Characterization of IM-42-44-05-H06-3CD3

[0214] FIG. 36 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence of IM-42-44-05-H06-3CD3 antibodies induced killing against human CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0215] FIGs. 37A, 37B, 37C, 37D, and 37E show cytokines produced by human PBMC cultured with IM-42-44-05-H06-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 37A shows the levels of IL-2, FIG. 37B shows the levels of IL-6, FIG. 37Cshows the levels of IL-10, FIG. 37D shows the levels of IFN-γ (gamma), and FIG. 37E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-05-H06-3CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by IM-42-44-05-H06-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0216] FIGs. 38A, 38B, 38C, 38D, and 38E shows cytokines produced by human PBMC cultured with IM-42-44-05-H06-3CD3 antibodies and human CLDN 18.1 - or 18.2-expressing cells. FIG. 38A shows the levels of IL-2, FIG. 38B shows the levels of IL-6, FIG. 38C shows the levels of IL-10, FIG. 38D shows the levels of IFN-γ (gamma), and FIG. 38E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-42-44-05-H06-3CD3 antibodies at the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL- 10, and IFN-γ were selectively induced in human PBMCs by the IM-42-44-05-H06-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 14: Functional Characterization of IM-21-44-09-B03-3CD3

[0217] FIG. 39 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence IM-21 -44-09-B03-3CD3 antibodies induced killing against CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0218] FIGs. 40A, 40B, 40C, 40D, and 40E shows cytokines produced by human PBMC cultured with IM-21-44-09-B03-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 40A shows the levels of IL-2, FIG. 40B shows the levels of IL-6, FIG. 40C shows the levels of IL-10, FIG. 40D shows the levels of IFN-γ (gamma), and FIG. 40E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-21-44-09-B03-3CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs IM-21 -44-09-B03-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0219] FIGs. 41A, 41B, 41C, 41D, and 41E shows cytokines produced by human PBMC cultured with IM-21-44-09-B03-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 41A shows the levels of IL-2, FIG. 41B shows the levels of IL-6, FIG. 41C shows the levels of IL-10, FIG. 41D shows the levels of IFN-γ (gamma), and FIG. 41E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-21-44-09-B03-3CD3 antibodies al the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL-6, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by IM-21 -44-09-B03-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 15: Functional Characterization of IM-21-44-01-E10-3CD3

[0220] FIG. 42 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence IM-21-44-01-E10-3CD3 antibodies induced killing against human CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0221] FIGs. 43A, 43B, 43C, 43D, and 43E shows cytokines produced by human PBMC cultured with IM-21-44-01-E10-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 43A shows the levels of IL-2, FIG. 43B shows the levels of IL-6, FIG. 43C shows the levels of IL-10, FIG. 43D shows the levels of IFN-γ (gamma), and FIG. 43E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-21-44-01-E10-3CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs IM-21-44-01-E10-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0222] FIGs. 44A, 44B, 44C, 44D, and 44E shows cytokines produced by human PBMC cultured with IM-21-44-01-E10-3CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 44A shows the levels of IL-2, FIG. 44B shows the levels of IL-6, FIG. 44C shows the levels of IL-10, FIG. 44D shows the levels of IFN-γ (gamma), and FIG. 44E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-21-44-01-E10-3CD3 antibodies at the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL-6, IL- 10, IFN-γ, and TNF-α wereselectively induced in human PBMCs by IM-21-44-01-E10-3CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 16: Functional Characterization of IM -2-44-05- H06-1 CD3

[0223] FIG. 45 is a graph of cellular toxicity data from T-cell dependent cellular cytotoxicity experiments. Human T cells (25,000 cells / well) co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells (2500 cells / well) in the presence IM-2-44-05-H06-1CD3 antibodies induced killing against human CLDN 18.2-expressing cells but not human CLDN 18.1 -expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.

[0224] FIGs. 46A, 46B, 46C, 46D, and 46E shows cytokines produced by human PBMC cultured with IM-2-44-05-H06-1CD3 antibodies and human CLDN 18.1 or 18.2 expressing cells. FIG. 46A shows the levels of IL-2, FIG. 46B shows the levels of IL-6, FIG. 46C shows the levels of IL-10, FIG. 46D shows the levels of IFN-γ (gamma), and FIG. 46E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-2-44-05-H06-1CD3 antibodies at the 24 hour (24hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs IM-2-44-01-H06-1CD3 antibody in the presence of human CLDN 18.2-expressing cells.

[0225] FIGs. 47A, 47B, 47C, 47D, and 47E shows cytokines produced by human PBMC cultured with IM-2-44-05-H06-1CD3 antibodies and human CLDN 18.1- or 18.2-expressing cells. FIG. 47A shows the levels of IL-2, FIG. 47B shows the levels of IL-6, FIG. 47C shows the levels of IL-10, FIG. 47D shows the levels of IFN-γ (gamma), and FIG. 47E shows the levels of TNF-α (alpha) produced by human PBMC in the presence of human CLDN 18.1- or 18.2-expressing cells and IM-2-44-05-H06-1CD3 antibodies at the 48 hour (48hr) timepoint. These experiments showed that IL-2, IL- 10, IFN-γ, and TNF-α were selectively induced in human PBMCs by IM-2-44-05-H06-1CD3 antibody in the presence of human CLDN 18.2-expressing cells.Example 17: mRNA Production of Antibodies Specific for Claudin 18.2 in T-cellDependent Cellular Cytotoxicity AssayMaterials and Methods

[0226] HEK293T cells were plated at 1,250 cells (control Cells: CLDN18.1 -positive HEK293T w / ffLuc, P29; target Cells: CLDN18.2-positive HEK293T w / ffLuc, P34) per well in a 384 well plate. The next day, the cells were transfected with mRNA encoding a respective antibody described in TABLE 13 starting at 0.05 μg and titrated by 1 / 4 A-H in two columns for each mRNA product. Columns that be administered antibody protein were treated with the same titration of lipofectamine without mRNA. The same day as transfection, antibody protein controls were added to the plate along with the T-cells (Lot 08152022) in a T-cell Dependent Cellular Cytotoxicity (TDCC) assay, as described throughout Examples 2- 16. Briefly, in the TDCC assay, control and target cells were harvested, and seeded at 1,250 cells / well. On the next day, mRNA in lipofectamine or just lipofectamine was added to cells. A column for each mRNA construct was left without T-cells to determine if mRNA transfection caused cell death. In wells that were not administered mRNA, protein controls were added. Next, T-cells were thawed and 25,000 were seeded. At 24 hours, 5 μL / well was collected for cytokine analysis. At 48 hours, 25 μL / well was collected for cytokine analysis. The Bright-Glo Substrate was added, and luminescence was read to measure killing. For data analysis, data was processed for control correction and organization using R and all curve fitting and graphing was done in GraphPad Prism 9. Non-linear Regression (curve fit) - log(agonist) vs. response (three parameters) for fitting were used. Testing conditions are listed in TABLE 14 and the results of the TDCC assay are provided in FIG. 48 and TABLE 15.

[0227] FIG. 48 is a graph of cellular toxicity data from TDCC experiments. Human T cells co-cultured with human CLDN 18.1 or CLDN 18.2-expressing ffLuciferase HEK293F cells in the presence of mRNA encoding IM-2-44-09B03-1CD3 or IM-16-44-09B03-1CD3 antibodies induced killing against human CLDN 18.2-expressing cells but not human CLDN 18.1-expressing cells. After 48 hour incubation at 37 °C, luciferase activity was detected using a Bright-Glo luciferase assay kit (Promega) and percent cell killing was calculated.TABLE 13TABLE 14TABLE 15

[0228] The data show that both mRNA molecules were able to kill their target cell lines at a comparable rate with the IM-16-44-09B03-1CD3 being slightly more efficient than IM-2-44- 09B03-1CD3. This result was unexpected, as the IM-16-44-09B03-1CD3 protein reference is considerably better at killing, however the finding could be due to expression since the IM-2- 44-09B03-1CD3 is just one plasmid so more mRNA is being transfected. Meanwhile, reference and control killing was observed, as expected.

[0229] All of the features disclosed herein may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

[0230] From the above description, one skilled in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the disclosure to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

Claims

CLAIMS1. A composition comprising an scFv-Fab IgG antibody specific for Claudin 18.2 and CD3 comprising: a first heavy chain, a second heavy chain, and a light chain, wherein:(a) the first heavy chain is selected from:(i)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, or (ii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 4767), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof;, or(iii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY1CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(b) the second heavy chain is selected from:(i)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLASPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4168), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSY1SYWAY (SEQ ID NO: 6) or a variant thereof and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), or(ii)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRASPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4169),an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, or (iii)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSASPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE EMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3983), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) the light chain is selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKPGQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCG GYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSC QVTHEGSTVEKTVAPTECS (SEQ ID NO: 3576) or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQ KPGQAPVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGY DSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAV TVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQV THEGSTVEKTVAPTECS (SEQ ID NO: 3593) or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQ QKPGQAPVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGG YDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQ VTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, ora light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof; optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

2. The composition of claim 1, wherein the Fc is from IgG.

3. The composition of claim 2, wherein the IgG is human IgG.

4. The composition of claim 3, wherein the human IgG is selected from IgGl, IgG2,IgG3, and IgG4.

5. The composition of any one of claims 2 to 4, wherein the antibody is formed through a knob-in-hole interaction in the Fc region.

6. The composition of any one of claims 3 to 5, wherein the human IgG Fc comprises one or mutations to promote knob-in-hole interactions.

7. The composition of claim 6, wherein the mutations are selected from (i) T366Y or T366W, and (ii) Y407T, Y407A, or Y407V.

8. The composition of claim 6, wherein the mutations are selected from:(a) T366Y and Y407T; or T366Y / F405A and T394W / Y407T in humanIgGl; or(b) T366W / D399C and T366S / L368A / K392C / Y407V;T366W / K392C and T366S / L368A / D399C / Y407V;S354C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and S354C / T366S / L368A / Y407V;E356C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and E356C / T366S / L368A / Y407V;E357C / T366W and Y349C / T366S / L368A / Y407V; orY349C / T366W and E357C / T366S / L368A / Y407V in human IgGl.

9. The composition of claim 3, wherein the human IgG Fc comprises one or mutations to reduce or eliminate the effector function of the Fc domains.

10. The composition of claim 9, wherein the mutations are L234A and L235A (LALA) substitutions in human IgGl.

11. The composition of claim 3, wherein the human IgG Fc comprises one or mutations to stabilize a hinge region in the Fc domain.

12. The composition of claim 11, wherein the mutation is S228P.

13. A composition comprising an IgG-scFv antibody specific for Claudin 18.2 and CD3 comprising:(a) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK (SEQ ID NO: 3869), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and(ii) the second heavy chain comprises:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4778), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, or(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4803), or an amino acid sequence having al least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, or(C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4806); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof; and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, or(b) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMS WVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSL RAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK (SEQ ID NO: 4767), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4779), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chainCDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4804), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and(C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPEEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4807); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chainCDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and / or heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, or(c) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAM MWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNS LRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP SREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4780), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof,(B)MKWVTFISLLFLFSSAYSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK (SEQ ID NO: 4805), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(C)MKWVTFISLLFLFSSAYSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTM HWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSL RPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDI QMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4808); or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWYQQKPGQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSC QVTHEGSTVEKTVAPTECS (SEQ ID NO: 3576), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQ KPGQAPVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGY DSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAV TVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQV THEGSTVEKTVAPTECS (SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQ QKPGQAPVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGG YDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQ VTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, ora light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof; optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

14. The composition of claim 13, wherein the Fc is from IgG.

15. The composition of claim 14, wherein the IgG is human IgG.

16. The composition of claim 15, wherein the human IgG is selected from IgGl, IgG2,IgG3, and IgG4.

17. The composition of any one of claims 13 to 16, wherein the antibody is formed through a knob-in-hole interaction in the Fc region.

18. The composition of any one of claims 15-17, wherein the human IgG Fc comprises one or mutations to promote knob-in-hole interaction.

19. The composition of claim 18, wherein the mutations are selected from:(i) T366Y or T366W; and(ii) Y407T, Y407A, or Y407V.

20. The composition of claim 18, wherein the mutations are selected from:(a) T366Y and Y407T; or T366Y / F405A and T394W / Y407T in humanIgGl; or(b) T366W / D399C and T366S / L368A / K392C / Y407V;T366W / K392C and T366S / L368A / D399C / Y407V;S354C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and S354C / T366S / L368A / Y407V;E356C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and E356C / T366S / L368A / Y407V;E357C / T366W and Y349C / T366S / L368A / Y407V; orY349C / T366W and E357C / T366S / L368A / Y407V, in human IgGl.

21. The composition of claim 15, wherein the human IgG Fc comprises one or mutations to reduce or eliminate the effector function of the Fc domains.

22. The composition of claim 21, wherein the mutations are L234A and L235A (LALA) substitutions in human IgGl .

23. The composition of claim 15, wherein the human IgG Fc comprises one or mutations to stabilize a hinge region in the Fc domain.

24. The composition of claim 23, wherein the mutation is S228P.

25. A composition comprising an IgG-(scFv)2antibody specific for Claudin 18.2 andCD3 comprising:(a) a heavy chain selected from:(i)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 4769), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), (ii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMG WVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLR AEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAP KRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTF GQGTKLQITR (SEQ ID NO: 4770), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, (iii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMG WVRQAPGKGLEWVAAITRDSSTNYGAAVKGRAT1SRDNSKNTLYLQMNSLR AEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCA ASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDN AKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS(SEQ ID NO: 4771), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence isCAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, (iv)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 4772), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence isVARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9),(v)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMDSLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITR (SEQ ID NO: 4773), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ IDNO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, (vi)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLM1SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCA ASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDN AKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 4774), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence isVAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, (vii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAM MWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNS LRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYA MNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGG GSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQ APRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN RWVFGGGTKLTVL (SEQ ID NO: 4775), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9), (viii)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAM MWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNS LRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGKGGGGSGGGGTGGGGSQVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYT MHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISTDKSKSTAFLQMD SLRPEDTAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGS DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSK LASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT R (SEQ ID NO: 4776), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GYTFTRYTMHWV (SEQ ID NO: 10) or a variant thereof, the heavy chain CDR2 sequence is IGYINPSRGYTNYNQ (SEQ ID NO: 11) or a variant thereof, and the heavy chain CDR3 sequence is CARYYDDHYCLDY (SEQ ID NO: 12) or a variant thereof, and / ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CSASSSVSYMN (SEQ ID NO: 13) or a variant thereof, the heavy chain CDR2 sequence is IYDTSKLASGVP (SEQ ID NO: 14) or a variant thereof, and the heavy chain CDR3 sequence is CQQWSSNPFTF (SEQ ID NO: 15) or a variant thereof, and (ix.)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAM MWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYS MGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQM TSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 4777), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWY QQKPGQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCG GYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSC QVTHEGSTVEKTVAPTECS (SEQ ID NO: 3576), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1 , CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQ KPGQAPVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGY DSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAV TVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQV THEGSTVEKTVAPTECS (SEQ ID NO: 3593), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, and(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQAPVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQ VTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1 , CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof; optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

26. The composition of claim 25, wherein the Fc is from IgG.

27. The composition of claim 26, wherein the IgG is human IgG.

28. The composition of claim 27, wherein the human IgG is selected from IgGl, IgG2,IgG3, and IgG4.

29. The composition of claim 26, wherein the human IgG Fc comprises one or mutations to reduce or eliminate the effector function of the Fc domains.

30. The composition of claim 29, wherein the mutations are L234A and L235A (LALA) substitutions in human IgGl.

31. The composition of claim 27, wherein the human IgG Fc comprises one or mutations to stabilize a hinge region in the Fc domain.

32. The composition of claim 31, wherein the mutation is S228P.

33. A composition comprising an IgG-(scFv) antibody specific for Claudin 18.2 and CD3 comprising:(a) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK (SEQ ID NO: 3869), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 5202), an amino acid sequence having at least about 90%, about 93%, about 95%, about97%, about 98%, or about 99% identity thereto, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMG WVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRDNSKNTLYLQMNSLR AEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSC AASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRD NAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS(SEQ ID NO: 5205), or an amino acid sequence having at least about 90%, about 93%, about 95%, about97%, about 98%, or about 99% identity thereto, ora heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence GFIFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the heavy chain CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the heavy chain CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, or(b) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK (SEQ ID NO: 4767), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSC AASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTIS RDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTV SSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYP NWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAE YYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 5203), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP(SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVAGIGSSGSDTWYADSVKGRFTISRDNSKNTLYLQMNSL RAEDTAVYYCAKDATNGYCWYTGRGSYSCGAHHIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSC AASGRTYRGYSMGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRD NAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 5206) or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1 , CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFSSYGMSWV (SEQ ID NO: 19) or a variant thereof, the heavy chain CDR2 sequence is VAGIGSSGSDTWYA (SEQ ID NO: 20) or a variant thereof, and the heavy chain CDR3 sequence is CAKDATNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 21) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, or(c) a first heavy chain and a second heavy chain, wherein(i) the first heavy chain comprises:MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4768), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and(ii) the second heavy chain is selected from:(A)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGTGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL (SEQ ID NO: 5204), oran amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the heavy chain CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the heavy chain CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the heavy chain CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the heavy chain CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, and(B)MKWVTFISLLFLFSSAYSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGKGGGGSGGGGTGGGGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYS MGWFRQAPGKEREFVAAIVWSGGNTYYEDSVKGRFTISRDNAKNTMYLQM TSLKPEDSATYYCAAKIRPYIFKIAGQYDYWGQGTQVTVSS (SEQ ID NO: 5207), oran amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the heavy chain CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the heavy chain CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence is GRTYRGYSMGW (SEQ ID NO: 16) or a variant thereof, the heavy chain CDR2 sequence is VAAIVWSGGNTYYE (SEQ ID NO: 17) or a variant thereof, and the heavy chain CDR3 sequence is CAAKIRPYIFKIAGQYDY (SEQ ID NO: 18) or a variant thereof, and(b) a light chain selected from:(i)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGSGSYGYYGWY QQKPGQAPVTVIYGTNKRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCG GYDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSC QVTHEGSTVEKTVAPTECS (SEQ ID NO: 3576), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGSGSYGYYG (SEQ ID NO: 25) or SGGSGSYGYYG (SEQ ID NO: 30) or a variant thereof, the light chain CDR2 sequence is IYGTNKRP (SEQ ID NO: 26) or GTNKRPS (SEQ ID NO: 32) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof,(ii)MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQ KPGQAPVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGY DSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQV THEGSTVEKTVAPTECS (SEQ ID NO: 3593), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1 , CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof, or(iii)MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQ QKPGQAPVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGG YDSSAGIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQ VTHEGSTVEKTVAPTECS (SEQ ID NO: 3817), an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or SGGYNGHYG (SEQ ID NO: 28) or a variant thereof, the light chain CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or SNNQRPS (SEQ ID NO: 31) or a variant thereof, and the light chain CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or GGYDSSAGI (SEQ ID NO: 33) or a variant thereof; optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

34. The composition of claim 33, wherein the Fc is from IgG.

35. The composition of claim 34, wherein the IgG is human IgG.

36. The composition of claim 35, wherein the human IgG is selected from IgGl, IgG2,IgG3, and IgG4.

37. The composition of any one of claims 33 to 36, wherein the antibody is formed through a knob-in-hole interaction in the Fc region.

38. The composition of claim 34 or claim 36, wherein the human IgG Fc comprises one or mutations to promote knob-in-hole interaction.

39. The composition of claim 38, wherein the mutations are selected from (i) T366Y or T366W, and (ii) Y407T, Y407A, or Y407V.

40. The composition of claim 38, wherein the mutations are selected from:(a) T366Y and Y407T or T366Y / F405A and T394W / Y407T in humanIgGl, and(b) T366W / D399C and T366S / L368A / K392C / Y407V;T366W / K392C and T366S / L368A / D399C / Y407V;S354C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and S354C / T366S / L368A / Y407V;E356C / T366W and Y349C / T366S / L368A / Y407V;Y349C / T366W and E356C / T366S / L368A / Y407V;E357C / T366W and Y349C / T366S / L368A / Y407V; orY349C / T366W and E357C / T366S / L368A / Y407V, in human IgGl.

41. The composition of claim 35, wherein the human IgG Fc comprises one or mutations to reduce or eliminate the effector function of the Fc domains.

42. The composition of claim 41, wherein the mutations are L234A and L235A (LALA) substitutions in human IgGl.

43. The composition of claim 35, wherein the human IgG Fc comprises one or mutations to stabilize a hinge region in the Fc domain.

44. The composition of claim 43, wherein the mutation is S228P.

45. A composition comprising a tandem single-chain variable fragment (scFv) specific forClaudin 18.2 and CD3 comprising one or more of:(a) an amino acid sequence of:MKWVTFISLLFLFSSAYSSYVLTQPPSVSVAPGKTARITCSGGYNGHYGWYQQKPGQAPVLVIYSNNQRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCGGYDSSAGIFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMMWVRQAPGKGLEWVGEISSTGGSTYYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSTYGATWKSADSIDAWGQGTLVTVSSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFL APGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL (SEQ ID: 4816), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or a variant thereof, the CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or a variant thereof, and the CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFRSYAMMWV (SEQ ID NO: 22) or a variant thereof, the CDR2 sequence is VGEISSTGGSTYYG (SEQ ID NO: 23) or a variant thereof, and the CDR3 sequence is CAKSTYGATWKSADSIDA (SEQ ID NO: 24) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9) or a variant thereof, or (b) an amino acid sequence of:MKWVTFISLLFLFSSAYSSYELTQPPSVSVSPGQTARITCSGGYNGHYGWYQQ KPGQAPVTVIYSNNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCGGY DSSAGIFGGGTKLTVLGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLS CAASGFTFSSYGMGWVRQAPGKGLEWVAAITRDSSTNYGAAVKGRATISRD NSKNTLYLQMNSLRAEDTAVYYCAKDASNGYCWYTGRGSYSCGAHHIDAW GQGTLVTVSSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNW VRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNN LKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGL IGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFG GGTKLTVL (SEQ ID NO. 4814), or an amino acid sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity thereto, or a variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is CSGGYNGHYG (SEQ ID NO: 34) or a variant thereof, the CDR2 sequence is IYSNNQRP (SEQ ID NO: 35) or a variant thereof, and the CDR3 sequence is CGGYDSSAGIF (SEQ ID NO: 27) or a variant thereof, and / or a variable region comprising CDR1 , CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFSSYGMGWV (SEQ ID NO: 1) or a variant thereof, the CDR2 sequence is VAAITRDSSTNYG (SEQ ID NO: 2) or a variant thereof, and the CDR3 sequence is CAKDASNGYCWYTGRGSYSCGAHHIDA (SEQ ID NO: 3) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is GFTFNKYAMNWV (SEQ ID NO: 4) or a variant thereof, the CDR2 sequence is VARIRSKYNNYATYYA (SEQ ID NO: 5) or a variant thereof, and the CDR3 sequence is CVRHGNFGNSYISYWAY (SEQ ID NO: 6) or a variant thereof, and / or a variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence is CGSSTGAVTSGNYP (SEQ ID NO: 7) or a variant thereof, the CDR2 sequence is IGGTKFLAP (SEQ ID NO: 8) or a variant thereof, and the CDR3 sequence is CVLWYSNRWVF (SEQ ID NO: 9); optionally wherein the first or second heavy chain comprises a His6 tag (e.g., HHHHHH (SEQ ID NO: 46)) added to the N- or C -terminus; and / or optionally wherein the composition comprises a linker comprising one or more glycines and serines replaced with another peptide linker or functionally equivalent variation thereof.

46. The composition of any one of claims 1 to 45, wherein the composition binds Claudin 18.2 and CD3 contemporaneously.

47. The composition of any one of claims 1 to 46, wherein the composition binds Claudin18.2 with an affinity of less than 10 nM and with at least 100-fold greater affinity than Claudin 9, Claudin 3, and / or Claudin 4.

48. The composition of any one of claims 1 to 45, wherein the first heavy chain, the second heavy chain, the light chain, and / or the single-chain variable fragment does not comprise: (a) amino acids 1-18 relative to the respective SEQ ID NO; and (b) the amino acid sequence MKWVTFISLLFLFSSAYS (SEQ ID NO: 5356).

49. A pharmaceutical composition comprising the antibody of any one of claims 1 to 48 or a nucleic acid molecule encoding the same.

50. The pharmaceutical composition of claim 49, wherein the composition is an injectable pharmaceutical composition.

51. The pharmaceutical composition of claim 49 or 50, wherein the pharmaceutical composition is sterile.

52. The pharmaceutical composition of any one of claims 49 to 51, wherein the pharmaceutical composition is pyrogen free.

53. A nucleic acid molecule encoding an antibody or an amino acid sequence of any of the preceding claims.

54. A vector comprising the nucleic acid molecule of claim 53.

55. A cell comprising the nucleic acid molecule of claim 53 or the vector of claim 54.

56. A method for modulating and / or targeting Claudin 18.2 and CD3 in a biological cell comprising contacting the cell with the composition or pharmaceutical composition of any one of claims 1 to 52.

57. A method for modulating Claudin 18.2 activity in a biological cell comprising contacting a cell expressing Claudin 18.2 with the composition or pharmaceutical composition of any one of claims 1 to 52.

58. A method for inhibiting the function of Claudin 18.2 in a biological cell comprising contacting a cell expressing Claudin 18.2 with the composition or pharmaceutical composition of any one of claims 1 to 52.

59. A method for treating or preventing cancer comprising administering an effective amount of the composition or pharmaceutical composition of any one of claims 1 to 52 to a subject in need thereof.

60. A use of the composition or pharmaceutical composition of any one of claims 1 to 52 for the preparation of a medicament for the treatment of prevention of cancer.

61. The method or use of claim 60, wherein the cancer is selected from one or more of basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestivesystem; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; glioma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; malignant rhabdoid tumor; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphoma including Hodgkin's and nonHodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular nonHodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and posttransplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses; edema (e.g. that associated with brain tumors); and Meigs’ syndrome.

62. An isolated antibody comprising one or more of the sequences disclosed herein.

63. A method of treating or preventing cancer comprising administering an effective amount of one or more of the nucleic acid molecules of claim 53 to a subject in need thereof.

64. The method of claim 63, wherein the cancer is selected from one or more of basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; glioma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; malignant rhabdoid tumor; rectal cancer; cancer of therespiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphoma including Hodgkin’s and non-Hodgkin’s lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin’s lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses; edema (e.g. that associated with brain tumors); and Meigs’ syndrome.

65. The method of claim 63 or 64, wherein the nucleic acid molecule comprises a sequence having at least about 90%, about 93%, about 95%, about 97%, about 98%, or about 99% identity to any one of SEQ ID NOs: 5329-5355.

Images